{
  "dataset": {
    "name": "pharmacy_copilot_pharmacist_eval_v1",
    "description": "Gold pharmacist scenarios for LLM evaluation (enriched for deterministic scoring).",
    "version": "1.2.0"
  },
  "metadata": {
    "question_count": 13,
    "evaluation_time": 34.151410818099976
  },
  "aggregated_metrics": {
    "retrieval": {
      "recall_at_k": {
        "1": 0.6538461538461539,
        "3": 0.9230769230769231,
        "5": 0.9230769230769231,
        "10": 0.9230769230769231,
        "20": 0.9230769230769231
      },
      "precision_at_k": {
        "1": 0.9230769230769231,
        "3": 0.5897435897435896,
        "5": 0.5897435897435896,
        "10": 0.5897435897435896,
        "20": 0.5897435897435896
      },
      "mean_reciprocal_rank": 0.9230769230769231,
      "average_precision": 0.9230769230769231,
      "ndcg_at_k": {
        "1": 0.9230769230769231,
        "3": 0.9230769230769231,
        "5": 0.9230769230769231,
        "10": 0.9230769230769231,
        "20": 0.9230769230769231
      },
      "essential_recall_at_k": {
        "1": 0.9230769230769231,
        "3": 0.9230769230769231,
        "5": 0.9230769230769231,
        "10": 0.9230769230769231,
        "20": 0.9230769230769231
      },
      "first_relevant_rank": 0.9230769230769231,
      "total_relevant": 19,
      "total_essential": 12
    },
    "qa": {
      "bleu_score": 0.03793511720375052,
      "rouge_1_f1": 0.3503872072958222,
      "rouge_2_f1": 0.1752500887671998,
      "rouge_l_f1": 0.26317604527126237,
      "semantic_similarity": 0.648184576859841,
      "key_points_covered": 0.3772893772893772,
      "key_points_found": [],
      "key_points_missing": [],
      "answer_length": 51,
      "has_answer": true,
      "factual_accuracy": null,
      "helpfulness": null
    }
  },
  "failure_cases": [
    {
      "question_id": "q001",
      "question": "5-year-old (18 kg) with acute otitis media. What is the amoxicillin dose and volume using 400 mg/5 mL suspension?",
      "failure_types": [
        "qa_incomplete"
      ],
      "retrieved_chunks": [
        {
          "chunk_id": "lexi-amoxicillin-2018#dosage",
          "score": 0.0,
          "rank": 1
        },
        {
          "chunk_id": "lexi-amoxicillin-2018#peds",
          "score": 0.0,
          "rank": 2
        },
        {
          "chunk_id": "lexi-amoxicillin-2018#adult-sinusitis",
          "score": 0.0,
          "rank": 3
        }
      ],
      "relevant_chunks_found": [
        "lexi-amoxicillin-2018#dosage",
        "lexi-amoxicillin-2018#peds"
      ],
      "essential_chunks_missed": [],
      "generated_answer": "{\n  \"dose_per_dose_mg\": 810,\n  \"volume_per_dose_mL\": 10.1,\n  \"frequency\": \"q12h\",\n  \"max_daily_mg\": 4000,\n  \"rounding\": \"rounding to practical mL is acceptable\",\n  \"calc_rule\": \"High-dose 80-90 mg/kg/day regimen; BID (q12h) frequency; Per-dose dose calculated as (18 kg * 80 mg/kg) / 5 mL (80 mg/mL); rounding to 10 mL OK; Max daily dose acknowledged\",\n  \"citations\": [\"lexi-amoxicillin-2018#dosage\"],\n  \"notes\": \"Uses high-dose 80-90 mg/kg/day regimen for pediatric AOM; BID (q12h) frequency; Per-dose ≈810 mg for 18 kg; Volume ≈10.1 mL",
      "expected_answer": "Amoxicillin 90 mg/kg/day divided q12h → 810 mg per dose (≈10.1 mL of 400 mg/5 mL), round to 10 mL per dose; max 4 g/day.",
      "key_points_missing": [
        "Max daily 4 g acknowledged",
        "No renal adjustment if normal function",
        "Cites pediatric dosage section"
      ],
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 0.5,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "precision_at_k": {
          "1": 1.0,
          "3": 0.6666666666666666,
          "5": 0.6666666666666666,
          "10": 0.6666666666666666,
          "20": 0.6666666666666666
        },
        "mean_reciprocal_rank": 1.0,
        "average_precision": 1.0,
        "ndcg_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "essential_recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "first_relevant_rank": 1,
        "total_relevant": 2,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.012665832537721989,
        "rouge_1_f1": 0.3934426229508196,
        "rouge_2_f1": 0.21666666666666665,
        "rouge_l_f1": 0.26229508196721313,
        "semantic_similarity": 0.8131217956542969,
        "key_points_covered": 0.5714285714285714,
        "key_points_found": [
          "Uses high-dose 80–90 mg/kg/day regimen",
          "BID (q12h) frequency",
          "Per-dose ≈810 mg for 18 kg",
          "Volume ≈10.1 mL from 400 mg/5 mL (80 mg/mL); rounding to 10 mL OK"
        ],
        "key_points_missing": [
          "Max daily 4 g acknowledged",
          "No renal adjustment if normal function",
          "Cites pediatric dosage section"
        ],
        "answer_length": 70,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "root_cause": "qa_system",
      "severity": "medium",
      "notes": null
    },
    {
      "question_id": "q002",
      "question": "12 kg child with fever: acetaminophen dose and volume using 160 mg/5 mL?",
      "failure_types": [
        "qa_incorrect",
        "qa_incomplete"
      ],
      "retrieved_chunks": [
        {
          "chunk_id": "lexi-acetaminophen-2018#peds-dosing",
          "score": 0.0,
          "rank": 1
        },
        {
          "chunk_id": "lexi-acetaminophen-2018#max",
          "score": 0.0,
          "rank": 2
        },
        {
          "chunk_id": "lexi-acetaminophen-2018#rectal",
          "score": 0.0,
          "rank": 3
        }
      ],
      "relevant_chunks_found": [
        "lexi-acetaminophen-2018#max",
        "lexi-acetaminophen-2018#peds-dosing"
      ],
      "essential_chunks_missed": [],
      "generated_answer": "{\n  \"dose_per_dose_mg\": 180,\n  \"volume_per_dose_mL\": 5.625,\n  \"frequency\": \"q6h\",\n  \"max_daily_mg\": 1440,\n  \"max_daily_mL\": null,\n  \"rounding\": \"rounded to one decimal\",\n  \"calc_rule\": \"15 mg/kg per dose, q4-6h, target q6h, 32 mg/mL\",\n  \"citations\": [\"lexi-acetaminophen-2018#peds-dosing\", \"lexi-acetaminophen-2018#max\"],\n  \"notes\": \"Pediatric dosing; liquid form\"\n}",
      "expected_answer": "Acetaminophen 15 mg/kg/dose q6h (range 10–15 mg/kg q4–6h) → 180 mg per dose ≈5.6 mL of 160 mg/5 mL; max 75 mg/kg/day (900 mg), and ≤4 g absolute.",
      "key_points_missing": [
        "Per-dose 15 mg/kg used",
        "q4–6h acceptable; target q6h in calc",
        "180 mg per dose for 12 kg",
        "Volume ≈5.625 mL from 32 mg/mL",
        "Daily max 75 mg/kg/day and ≤4 g",
        "Pediatric dosing section cited"
      ],
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 0.5,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "precision_at_k": {
          "1": 1.0,
          "3": 0.6666666666666666,
          "5": 0.6666666666666666,
          "10": 0.6666666666666666,
          "20": 0.6666666666666666
        },
        "mean_reciprocal_rank": 1.0,
        "average_precision": 1.0,
        "ndcg_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "essential_recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "first_relevant_rank": 1,
        "total_relevant": 2,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.00598648581729222,
        "rouge_1_f1": 0.3956043956043956,
        "rouge_2_f1": 0.0898876404494382,
        "rouge_l_f1": 0.2417582417582418,
        "semantic_similarity": 0.6589660048484802,
        "key_points_covered": 0.0,
        "key_points_found": [],
        "key_points_missing": [
          "Per-dose 15 mg/kg used",
          "q4–6h acceptable; target q6h in calc",
          "180 mg per dose for 12 kg",
          "Volume ≈5.625 mL from 32 mg/mL",
          "Daily max 75 mg/kg/day and ≤4 g",
          "Pediatric dosing section cited"
        ],
        "answer_length": 35,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "root_cause": "qa_system",
      "severity": "high",
      "notes": null
    },
    {
      "question_id": "q003",
      "question": "12 kg child with fever: ibuprofen dose and volume using 100 mg/5 mL?",
      "failure_types": [
        "qa_incomplete"
      ],
      "retrieved_chunks": [
        {
          "chunk_id": "lexi-ibuprofen-2018#peds-dosing",
          "score": 0.0,
          "rank": 1
        },
        {
          "chunk_id": "lexi-ibuprofen-2018#max",
          "score": 0.0,
          "rank": 2
        },
        {
          "chunk_id": "lexi-ibuprofen-2018#adult-capsules",
          "score": 0.0,
          "rank": 3
        }
      ],
      "relevant_chunks_found": [
        "lexi-ibuprofen-2018#max",
        "lexi-ibuprofen-2018#peds-dosing"
      ],
      "essential_chunks_missed": [],
      "generated_answer": "{\n  \"dose_per_dose_mg\": 120,\n  \"volume_per_dose_mL\": 6.0,\n  \"frequency\": \"q6-8h\",\n  \"max_daily_mg\": 480,\n  \"rounding\": \"round to nearest 0.1 mL\",\n  \"calc_rule\": \"10 mg/kg per dose, maximum 40 mg/kg/day\",\n  \"citations\": [\"lexi-ibuprofen-2018#peds-dosing\", \"lexi-ibuprofen-2018#max\"],\n  \"notes\": \"12 kg child with fever: 120 mg ibuprofen per dose (6 mL of 100 mg/5 mL suspension), q6-8h; maximum daily dose 480 mg; contraindicated in children under 6 months and use with caution in renal/dehydration risk\"\n}",
      "expected_answer": "Ibuprofen 10 mg/kg/dose q6–8h → 120 mg per dose (6 mL of 100 mg/5 mL); max 40 mg/kg/day (480 mg). Avoid if <6 months or dehydrated/renal issues.",
      "key_points_missing": [
        "q6–8h frequency",
        "6 mL at 20 mg/mL"
      ],
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 0.5,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "precision_at_k": {
          "1": 1.0,
          "3": 0.6666666666666666,
          "5": 0.6666666666666666,
          "10": 0.6666666666666666,
          "20": 0.6666666666666666
        },
        "mean_reciprocal_rank": 1.0,
        "average_precision": 1.0,
        "ndcg_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "essential_recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "first_relevant_rank": 1,
        "total_relevant": 2,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.0858745369038274,
        "rouge_1_f1": 0.48333333333333334,
        "rouge_2_f1": 0.28813559322033894,
        "rouge_l_f1": 0.3333333333333333,
        "semantic_similarity": 0.7715703248977661,
        "key_points_covered": 0.6666666666666666,
        "key_points_found": [
          "10 mg/kg per dose",
          "120 mg per dose for 12 kg",
          "Max 40 mg/kg/day (480 mg)",
          "Contraindication: <6 months; caution renal/dehydration"
        ],
        "key_points_missing": [
          "q6–8h frequency",
          "6 mL at 20 mg/mL"
        ],
        "answer_length": 64,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "root_cause": "qa_system",
      "severity": "medium",
      "notes": null
    },
    {
      "question_id": "q004",
      "question": "Elderly patient with nonvalvular AF: 82 years, 58 kg, SCr 1.6 mg/dL. What apixaban dose?",
      "failure_types": [
        "qa_incorrect",
        "qa_incomplete",
        "e2e_low_quality"
      ],
      "retrieved_chunks": [
        {
          "chunk_id": "lexi-apixaban-2018#dosing-nvaf",
          "score": 0.0,
          "rank": 1
        },
        {
          "chunk_id": "lexi-apixaban-2018#ddi",
          "score": 0.0,
          "rank": 2
        },
        {
          "chunk_id": "lexi-apixaban-2018#vte",
          "score": 0.0,
          "rank": 3
        }
      ],
      "relevant_chunks_found": [
        "lexi-apixaban-2018#ddi",
        "lexi-apixaban-2018#dosing-nvaf"
      ],
      "essential_chunks_missed": [],
      "generated_answer": "{\n  \"dose_per_dose_mg\": 2.5,\n  \"volume_per_dose_mL\": null,\n  \"frequency\": \"BID\",\n  \"max_daily_mg\": null,\n  \"rounding\": \"Not applicable (tablets)\",\n  \"calc_rule\": \"Dose reduction criteria: 2 of 3: age ≥80 years, weight ≤60 kg, or serum creatinine ≥1.5 mg/dL\",\n  \"citations\": [\"lexi-apixaban-2018#dosing-nvaf\"],\n  \"notes\": \"Avoid strong CYP3A4/P-gp inhibitors/inducers and assess hepatic impairment.\"",
      "expected_answer": "Apixaban 2.5 mg BID (meets 2 of 3: age ≥80, weight ≤60 kg, SCr ≥1.5). Avoid with strong CYP3A4/P-gp inhibitors.",
      "key_points_missing": [
        "Final dose 2.5 mg BID",
        "Interaction caveat: strong CYP3A4/P-gp",
        "Hepatic impairment caution"
      ],
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 0.5,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "precision_at_k": {
          "1": 1.0,
          "3": 0.6666666666666666,
          "5": 0.6666666666666666,
          "10": 0.6666666666666666,
          "20": 0.6666666666666666
        },
        "mean_reciprocal_rank": 1.0,
        "average_precision": 1.0,
        "ndcg_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "essential_recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "first_relevant_rank": 1,
        "total_relevant": 2,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.09889276153808085,
        "rouge_1_f1": 0.4999999999999999,
        "rouge_2_f1": 0.3170731707317073,
        "rouge_l_f1": 0.45238095238095233,
        "semantic_similarity": 0.5738503932952881,
        "key_points_covered": 0.25,
        "key_points_found": [
          "Dose reduction criteria (2 of 3)"
        ],
        "key_points_missing": [
          "Final dose 2.5 mg BID",
          "Interaction caveat: strong CYP3A4/P-gp",
          "Hepatic impairment caution"
        ],
        "answer_length": 42,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "root_cause": "qa_system",
      "severity": "high",
      "notes": null
    },
    {
      "question_id": "q005",
      "question": "85 kg adult with acute DVT: What is the enoxaparin treatment dose (normal renal function)?",
      "failure_types": [
        "qa_incomplete"
      ],
      "retrieved_chunks": [
        {
          "chunk_id": "lexi-enoxaparin-2018#dosing",
          "score": 0.0,
          "rank": 1
        },
        {
          "chunk_id": "lexi-enoxaparin-2018#renal",
          "score": 0.0,
          "rank": 2
        },
        {
          "chunk_id": "lexi-enoxaparin-2018#prophylaxis",
          "score": 0.0,
          "rank": 3
        }
      ],
      "relevant_chunks_found": [
        "lexi-enoxaparin-2018#dosing",
        "lexi-enoxaparin-2018#renal"
      ],
      "essential_chunks_missed": [],
      "generated_answer": "{\n  \"dose_per_dose_mg\": 85,\n  \"volume_per_dose_mL\": null,\n  \"frequency\": \"q12h\",\n  \"max_daily_mg\": null,\n  \"rounding\": \"Rounded to nearest whole number\",\n  \"calc_rule\": \"1 mg/kg q12h (primary regimen) or 1.5 mg/kg q24h (alternative), adjusted for renal function (CrCl <30: 1 mg/kg q24h)\",\n  \"citations\": [\"lexi-enoxaparin-2018#dosing\"],\n  \"notes\": \"Renal adjustment for CrCl <30 may be necessary\"\n}",
      "expected_answer": "Enoxaparin 1 mg/kg SC q12h → 85 mg per dose (or 1.5 mg/kg once daily as alternative). If CrCl <30 mL/min: 1 mg/kg once daily.",
      "key_points_missing": [
        "Per-dose 85 mg for 85 kg"
      ],
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 0.5,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "precision_at_k": {
          "1": 1.0,
          "3": 0.6666666666666666,
          "5": 0.6666666666666666,
          "10": 0.6666666666666666,
          "20": 0.6666666666666666
        },
        "mean_reciprocal_rank": 1.0,
        "average_precision": 1.0,
        "ndcg_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "essential_recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "first_relevant_rank": 1,
        "total_relevant": 2,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.024771004662276757,
        "rouge_1_f1": 0.48888888888888893,
        "rouge_2_f1": 0.22727272727272724,
        "rouge_l_f1": 0.3333333333333333,
        "semantic_similarity": 0.7317655682563782,
        "key_points_covered": 0.75,
        "key_points_found": [
          "1 mg/kg q12h primary regimen",
          "Alternative 1.5 mg/kg q24h",
          "Renal adjustment for CrCl <30"
        ],
        "key_points_missing": [
          "Per-dose 85 mg for 85 kg"
        ],
        "answer_length": 47,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "root_cause": "qa_system",
      "severity": "medium",
      "notes": null
    },
    {
      "question_id": "q006",
      "question": "Type 2 diabetes patient with eGFR 28 mL/min/1.73 m². Can we use metformin?",
      "failure_types": [
        "qa_incorrect",
        "qa_incomplete"
      ],
      "retrieved_chunks": [
        {
          "chunk_id": "lexi-metformin-2018#renal",
          "score": 0.0,
          "rank": 1
        },
        {
          "chunk_id": "lexi-metformin-2018#contra",
          "score": 0.0,
          "rank": 2
        },
        {
          "chunk_id": "lexi-metformin-2018#old-crcl60",
          "score": 0.0,
          "rank": 3
        }
      ],
      "relevant_chunks_found": [
        "lexi-metformin-2018#contra",
        "lexi-metformin-2018#renal"
      ],
      "essential_chunks_missed": [],
      "generated_answer": "{\n  \"dose_per_dose_mg\": null,\n  \"volume_per_dose_mL\": null,\n  \"frequency\": null,\n  \"max_daily_mg\": null,\n  \"rounding\": \"Not applicable\",\n  \"calc_rule\": \"Contraindicated if eGFR <30, avoid initiation if 30-45, continue with dose reduction and monitoring\",\n  \"citations\": [\"lexi-metformin-2018#renal\"],\n  \"notes\": \"Metformin is contraindicated in eGFR <30 mL/min/1.73 m², and should be avoided in initiation for eGFR 30-45. If continued, dose reduction and monitoring of renal function is necessary.\"",
      "expected_answer": "No—contraindicated at eGFR <30. If 30–45, generally avoid initiation; if continuing, reduce dose and monitor. Avoid in hepatic impairment.",
      "key_points_missing": [
        "30–45: avoid initiation; if continuing, reduce & monitor",
        "Hepatic impairment: avoid (lactic acidosis risk)"
      ],
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 0.5,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "precision_at_k": {
          "1": 1.0,
          "3": 0.6666666666666666,
          "5": 0.6666666666666666,
          "10": 0.6666666666666666,
          "20": 0.6666666666666666
        },
        "mean_reciprocal_rank": 1.0,
        "average_precision": 1.0,
        "ndcg_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "essential_recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "first_relevant_rank": 1,
        "total_relevant": 2,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.013195944411119548,
        "rouge_1_f1": 0.31578947368421056,
        "rouge_2_f1": 0.17204301075268816,
        "rouge_l_f1": 0.2736842105263158,
        "semantic_similarity": 0.6303442120552063,
        "key_points_covered": 0.3333333333333333,
        "key_points_found": [
          "Contraindicated if eGFR <30"
        ],
        "key_points_missing": [
          "30–45: avoid initiation; if continuing, reduce & monitor",
          "Hepatic impairment: avoid (lactic acidosis risk)"
        ],
        "answer_length": 58,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "root_cause": "qa_system",
      "severity": "high",
      "notes": null
    },
    {
      "question_id": "q007",
      "question": "Uncomplicated cystitis: Should we use nitrofurantoin if eGFR is 25?",
      "failure_types": [
        "qa_incomplete"
      ],
      "retrieved_chunks": [
        {
          "chunk_id": "lexi-nitrofurantoin-2018#renal",
          "score": 0.0,
          "rank": 1
        },
        {
          "chunk_id": "lexi-nitrofurantoin-2018#contra",
          "score": 0.0,
          "rank": 2
        },
        {
          "chunk_id": "lexi-nitrofurantoin-2018#prophylaxis",
          "score": 0.0,
          "rank": 3
        }
      ],
      "relevant_chunks_found": [
        "lexi-nitrofurantoin-2018#contra",
        "lexi-nitrofurantoin-2018#renal"
      ],
      "essential_chunks_missed": [],
      "generated_answer": "{\n  \"dose_per_dose_mg\": null,\n  \"volume_per_dose_mL\": null,\n  \"frequency\": null,\n  \"max_daily_mg\": null,\n  \"rounding\": \"Not applicable\",\n  \"calc_rule\": \"Avoid use if eGFR/CrCl <30 mL/min due to inadequate urinary concentrations and increased toxicity risk (lexi-nitrofurantoin-2018#renal)\",\n  \"citations\": [\"lexi-nitrofurantoin-2018#renal\"],\n  \"notes\": \"Avoid nitrofurantoin in eGFR/CrCl <30 mL/min due to efficacy and toxicity concerns. Common contraindications include significant renal dysfunction (lexi-nitrofurantoin-2018#contra).\"\n}",
      "expected_answer": "Avoid nitrofurantoin when eGFR/CrCl <30 mL/min due to low urinary levels and toxicity risk.",
      "key_points_missing": [
        "Rationale: efficacy/toxicity",
        "List common contraindications where relevant"
      ],
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 0.5,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "precision_at_k": {
          "1": 1.0,
          "3": 0.6666666666666666,
          "5": 0.6666666666666666,
          "10": 0.6666666666666666,
          "20": 0.6666666666666666
        },
        "mean_reciprocal_rank": 1.0,
        "average_precision": 1.0,
        "ndcg_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "essential_recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "first_relevant_rank": 1,
        "total_relevant": 2,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.05634113296924294,
        "rouge_1_f1": 0.29545454545454547,
        "rouge_2_f1": 0.20930232558139536,
        "rouge_l_f1": 0.27272727272727276,
        "semantic_similarity": 0.8060358166694641,
        "key_points_covered": 0.3333333333333333,
        "key_points_found": [
          "Avoid if eGFR/CrCl <30"
        ],
        "key_points_missing": [
          "Rationale: efficacy/toxicity",
          "List common contraindications where relevant"
        ],
        "answer_length": 52,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "root_cause": "qa_system",
      "severity": "medium",
      "notes": null
    },
    {
      "question_id": "q008",
      "question": "Patient on warfarin needs TMP-SMX for UTI. Any interaction and what should we do?",
      "failure_types": [
        "retrieval_irrelevant",
        "qa_incorrect",
        "qa_incomplete"
      ],
      "retrieved_chunks": [
        {
          "chunk_id": "lexi-warfarin-2018#ddi-tmp-smx",
          "score": 0.0,
          "rank": 1
        },
        {
          "chunk_id": "lexi-warfarin-2018#ddi-cephalexin",
          "score": 0.0,
          "rank": 2
        }
      ],
      "relevant_chunks_found": [
        "lexi-warfarin-2018#ddi-tmp-smx"
      ],
      "essential_chunks_missed": [],
      "generated_answer": "{\n  \"dose_per_dose_mg\": null,\n  \"volume_per_dose_mL\": null,\n  \"frequency\": \"q12h\",\n  \"max_daily_mg\": null,\n  \"rounding\": \"round to nearest 5mg\",\n  \"calc_rule\": \"Avoid TMP-SMX due to major interaction (CYP2C9 inhibition and gut flora changes), leading to increased INR. If used, reduce warfarin dose and increase INR monitoring.\",\n  \"citations\": [\"lexi-warfarin-2018#ddi-tmp-smx\"],\n  \"notes\": \"Avoid TMP-SMX with warfarin; close INR monitoring with dose reduction if used.\"\n}",
      "expected_answer": "Major interaction (CYP2C9 inhibition + gut flora). Avoid if possible; otherwise increase INR monitoring and reduce warfarin dose.",
      "key_points_missing": [
        "Severity: major"
      ],
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "precision_at_k": {
          "1": 1.0,
          "3": 0.5,
          "5": 0.5,
          "10": 0.5,
          "20": 0.5
        },
        "mean_reciprocal_rank": 1.0,
        "average_precision": 1.0,
        "ndcg_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "essential_recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "first_relevant_rank": 1,
        "total_relevant": 1,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.060594492461490825,
        "rouge_1_f1": 0.3448275862068966,
        "rouge_2_f1": 0.18823529411764708,
        "rouge_l_f1": 0.2758620689655173,
        "semantic_similarity": 0.6212816834449768,
        "key_points_covered": 0.6666666666666666,
        "key_points_found": [
          "Mechanism: CYP2C9 inhibition + gut flora",
          "Action: avoid or close INR monitoring with dose reduction"
        ],
        "key_points_missing": [
          "Severity: major"
        ],
        "answer_length": 56,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "root_cause": "both_systems",
      "severity": "high",
      "notes": null
    },
    {
      "question_id": "q009",
      "question": "Patient on atorvastatin needs clarithromycin. What’s the risk and action?",
      "failure_types": [
        "retrieval_irrelevant",
        "qa_incorrect",
        "qa_incomplete"
      ],
      "retrieved_chunks": [
        {
          "chunk_id": "lexi-atorvastatin-2018#ddi-macrolides",
          "score": 0.0,
          "rank": 1
        },
        {
          "chunk_id": "lexi-atorvastatin-2018#ddi-azithro",
          "score": 0.0,
          "rank": 2
        }
      ],
      "relevant_chunks_found": [
        "lexi-atorvastatin-2018#ddi-macrolides"
      ],
      "essential_chunks_missed": [],
      "generated_answer": "{\n  \"dose_per_dose_mg\": null,\n  \"volume_per_dose_mL\": null,\n  \"frequency\": null,\n  \"max_daily_mg\": null,\n  \"rounding\": \"Not applicable\",\n  \"calc_rule\": \"Strong CYP3A4 inhibition increases atorvastatin levels and myopathy/rhabdomyolysis risk; avoid; if unavoidable, hold or use the lowest dose with close monitoring\",\n  \"citations\": [\"lexi-atorvastatin-2018#ddi-macrolides\"],\n  \"notes\": \"Avoid coadministration of clarithromycin with atorvastatin due to increased risk of myopathy/rhabdomyolysis; if unavoidable, hold or use the lowest dose with close monitoring\"\n}",
      "expected_answer": "Major interaction (strong CYP3A4 inhibitor). Avoid coadministration; if unavoidable, hold atorvastatin or limit to the lowest dose and monitor for myopathy.",
      "key_points_missing": [
        "Severity: major"
      ],
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "precision_at_k": {
          "1": 1.0,
          "3": 0.5,
          "5": 0.5,
          "10": 0.5,
          "20": 0.5
        },
        "mean_reciprocal_rank": 1.0,
        "average_precision": 1.0,
        "ndcg_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "essential_recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "first_relevant_rank": 1,
        "total_relevant": 1,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.05262474629009886,
        "rouge_1_f1": 0.3368421052631579,
        "rouge_2_f1": 0.12903225806451613,
        "rouge_l_f1": 0.25263157894736843,
        "semantic_similarity": 0.621039867401123,
        "key_points_covered": 0.6666666666666666,
        "key_points_found": [
          "Mechanism: strong CYP3A4 inhibition",
          "Action: avoid; if unavoidable hold or use lowest dose with monitoring"
        ],
        "key_points_missing": [
          "Severity: major"
        ],
        "answer_length": 61,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "root_cause": "both_systems",
      "severity": "high",
      "notes": null
    },
    {
      "question_id": "q010",
      "question": "Starting linezolid in a patient on sertraline. Is this safe?",
      "failure_types": [
        "retrieval_irrelevant",
        "qa_incorrect",
        "qa_incomplete",
        "e2e_low_quality"
      ],
      "retrieved_chunks": [
        {
          "chunk_id": "lexi-linezolid-2018#ddi-ssri",
          "score": 0.0,
          "rank": 1
        },
        {
          "chunk_id": "lexi-linezolid-2018#ddi-penicillins",
          "score": 0.0,
          "rank": 2
        }
      ],
      "relevant_chunks_found": [
        "lexi-linezolid-2018#ddi-ssri"
      ],
      "essential_chunks_missed": [],
      "generated_answer": "{\n  \"dose_per_dose_mg\": null,\n  \"volume_per_dose_mL\": null,\n  \"frequency\": null,\n  \"max_daily_mg\": null,\n  \"rounding\": \"Not applicable\",\n  \"calc_rule\": \"Avoid combination due to Linezolid's reversible MAOI activity precipitating serotonin syndrome with SSRIs\",\n  \"citations\": [\"lexi-linezolid-2018#ddi-ssri\"],\n  \"notes\": \"Avoid Linezolid in patients on Sertraline due to risk of serotonin syndrome\"\n}",
      "expected_answer": "Major interaction: risk of serotonin syndrome (linezolid has MAOI activity). Avoid; if benefits outweigh risks, withhold SSRI or monitor very closely.",
      "key_points_missing": [
        "Mechanism: MAOI activity → ↑serotonin",
        "Severity: major",
        "Action: avoid; or stop SSRI/close monitoring if unavoidable"
      ],
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "precision_at_k": {
          "1": 1.0,
          "3": 0.5,
          "5": 0.5,
          "10": 0.5,
          "20": 0.5
        },
        "mean_reciprocal_rank": 1.0,
        "average_precision": 1.0,
        "ndcg_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "essential_recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "first_relevant_rank": 1,
        "total_relevant": 1,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.03539596914884462,
        "rouge_1_f1": 0.24,
        "rouge_2_f1": 0.10958904109589042,
        "rouge_l_f1": 0.13333333333333333,
        "semantic_similarity": 0.5741615891456604,
        "key_points_covered": 0.0,
        "key_points_found": [],
        "key_points_missing": [
          "Mechanism: MAOI activity → ↑serotonin",
          "Severity: major",
          "Action: avoid; or stop SSRI/close monitoring if unavoidable"
        ],
        "answer_length": 42,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "root_cause": "both_systems",
      "severity": "high",
      "notes": null
    },
    {
      "question_id": "q011",
      "question": "Patient on digoxin will start amiodarone. What’s the interaction management?",
      "failure_types": [
        "retrieval_irrelevant",
        "qa_incomplete"
      ],
      "retrieved_chunks": [
        {
          "chunk_id": "lexi-digoxin-2018#ddi-amio",
          "score": 0.0,
          "rank": 1
        },
        {
          "chunk_id": "lexi-digoxin-2018#ddi-verapamil",
          "score": 0.0,
          "rank": 2
        }
      ],
      "relevant_chunks_found": [
        "lexi-digoxin-2018#ddi-amio"
      ],
      "essential_chunks_missed": [],
      "generated_answer": "{\n  \"dose_per_dose_mg\": null,\n  \"volume_per_dose_mL\": null,\n  \"frequency\": \"qd\",\n  \"max_daily_mg\": null,\n  \"rounding\": \"Not applicable\",\n  \"calc_rule\": \"P-gp inhibition ↑ digoxin dose by ~30-50%, monitor serum levels, renal function, and ECG (3 criteria met)\",\n  \"citations\": [\"lexi-digoxin-2018#ddi-amio\"],\n  \"notes\": \"Reduce digoxin dose by 30-50% when starting amiodarone, monitor digoxin levels, renal function, and ECG\"",
      "expected_answer": "Major interaction (P-gp inhibition). Reduce digoxin dose by ~30–50% and monitor levels/ECG.",
      "key_points_missing": [
        "Mechanism: P-gp inhibition → ↑digoxin",
        "Severity: major"
      ],
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "precision_at_k": {
          "1": 1.0,
          "3": 0.5,
          "5": 0.5,
          "10": 0.5,
          "20": 0.5
        },
        "mean_reciprocal_rank": 1.0,
        "average_precision": 1.0,
        "ndcg_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "essential_recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "first_relevant_rank": 1,
        "total_relevant": 1,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.030177341354967666,
        "rouge_1_f1": 0.33766233766233766,
        "rouge_2_f1": 0.18666666666666668,
        "rouge_l_f1": 0.3116883116883117,
        "semantic_similarity": 0.7093247175216675,
        "key_points_covered": 0.3333333333333333,
        "key_points_found": [
          "Action: reduce dose ~30–50% + monitor levels and ECG"
        ],
        "key_points_missing": [
          "Mechanism: P-gp inhibition → ↑digoxin",
          "Severity: major"
        ],
        "answer_length": 48,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "root_cause": "both_systems",
      "severity": "medium",
      "notes": null
    },
    {
      "question_id": "q012",
      "question": "COVID-19 patient asks for Paxlovid dosing and interaction checks.",
      "failure_types": [
        "retrieval_miss",
        "retrieval_irrelevant",
        "qa_incorrect",
        "qa_incomplete",
        "e2e_low_quality"
      ],
      "retrieved_chunks": [
        {
          "chunk_id": "kb-scope-2018#covid-absent",
          "score": 0.0,
          "rank": 1
        }
      ],
      "relevant_chunks_found": [],
      "essential_chunks_missed": [],
      "generated_answer": "{\n  \"dose_per_dose_mg\": null,\n  \"volume_per_dose_mL\": null,\n  \"frequency\": \"q12h\",\n  \"max_daily_mg\": null,\n  \"rounding\": \"Rounded to whole tablet\",\n  \"calc_rule\": \"Recency-sensitive; abstain and refer to current guidance/pharmacist\",\n  \"citations\": [\"kb-scope-2018#covid-absent\"],\n  \"notes\": \"COVID-19 therapies (e.g., nirmatrelvir/ritonavir) are not covered in this context; refer to current guidance.\"",
      "expected_answer": "ABSTAIN. Not in ≤2018 corpus; recency-sensitive therapy. Advise consulting current guidance/pharmacist.",
      "key_points_missing": [
        "Explicit abstention",
        "Sets recency_risk = true",
        "Advises pharmacist/current guidance"
      ],
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "precision_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "mean_reciprocal_rank": 0.0,
        "average_precision": 0.0,
        "ndcg_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "essential_recall_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "first_relevant_rank": 0.0,
        "total_relevant": 0,
        "total_essential": 0
      },
      "qa_metrics": {
        "bleu_score": 0.006009853514400763,
        "rouge_1_f1": 0.2898550724637681,
        "rouge_2_f1": 0.08955223880597014,
        "rouge_l_f1": 0.14492753623188406,
        "semantic_similarity": 0.47531673312187195,
        "key_points_covered": 0.0,
        "key_points_found": [],
        "key_points_missing": [
          "Explicit abstention",
          "Sets recency_risk = true",
          "Advises pharmacist/current guidance"
        ],
        "answer_length": 39,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "root_cause": "both_systems",
      "severity": "high",
      "notes": null
    },
    {
      "question_id": "q013",
      "question": "What is the current first-line pharmacologic therapy per latest hypertension guidelines?",
      "failure_types": [
        "qa_incorrect",
        "qa_incomplete",
        "e2e_low_quality"
      ],
      "retrieved_chunks": [
        {
          "chunk_id": "lexi-hypertension-2014#jnc8",
          "score": 0.0,
          "rank": 1
        }
      ],
      "relevant_chunks_found": [
        "lexi-hypertension-2014#jnc8"
      ],
      "essential_chunks_missed": [],
      "generated_answer": "{\n  \"dose_per_dose_mg\": null,\n  \"volume_per_dose_mL\": null,\n  \"frequency\": \"q12h\",\n  \"max_daily_mg\": null,\n  \"rounding\": \"Rounded to nearest whole number\",\n  \"calc_rule\": \"First-line pharmacologic therapy per JNC8 (2014) guidelines not recommended as current; recency_risk = true\",\n  \"citations\": [\"lexi-hypertension-2014#jnc8\"],\n  \"notes\": \"First-line pharmacologic therapy per JNC8 (2014) is not the current recommendation due to recency risk.\"\n}",
      "expected_answer": "ABSTAIN if asked for ‘current’ guidance (2018 corpus includes JNC8/2014). Flag recency risk.",
      "key_points_missing": [
        "Explicit abstention for ‘current’ guideline ask",
        "Recognize JNC8 (2014) is outdated for ‘current’"
      ],
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "precision_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "mean_reciprocal_rank": 1.0,
        "average_precision": 1.0,
        "ndcg_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "essential_recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "first_relevant_rank": 1,
        "total_relevant": 1,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.010626422039392276,
        "rouge_1_f1": 0.13333333333333333,
        "rouge_2_f1": 0.0547945205479452,
        "rouge_l_f1": 0.13333333333333333,
        "semantic_similarity": 0.4396207928657532,
        "key_points_covered": 0.3333333333333333,
        "key_points_found": [
          "Sets recency_risk = true"
        ],
        "key_points_missing": [
          "Explicit abstention for ‘current’ guideline ask",
          "Recognize JNC8 (2014) is outdated for ‘current’"
        ],
        "answer_length": 49,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "root_cause": "qa_system",
      "severity": "high",
      "notes": null
    }
  ],
  "questions": [
    {
      "question_id": "q001",
      "question": {
        "id": "q001",
        "question": "5-year-old (18 kg) with acute otitis media. What is the amoxicillin dose and volume using 400 mg/5 mL suspension?",
        "question_type": "dosage",
        "difficulty": "medium",
        "expected_answer": "Amoxicillin 90 mg/kg/day divided q12h → 810 mg per dose (≈10.1 mL of 400 mg/5 mL), round to 10 mL per dose; max 4 g/day.",
        "answer_key_points": [
          "Uses high-dose 80–90 mg/kg/day regimen",
          "BID (q12h) frequency",
          "Per-dose ≈810 mg for 18 kg",
          "Volume ≈10.1 mL from 400 mg/5 mL (80 mg/mL); rounding to 10 mL OK",
          "Max daily 4 g acknowledged",
          "No renal adjustment if normal function",
          "Cites pediatric dosage section"
        ],
        "relevant_chunks": [
          {
            "chunk_id": "lexi-amoxicillin-2018#dosage",
            "relevance_score": 1.0,
            "is_essential": true,
            "note": null
          },
          {
            "chunk_id": "lexi-amoxicillin-2018#peds",
            "relevance_score": 1.0,
            "is_essential": false,
            "note": null
          }
        ],
        "drug_names": [
          "amoxicillin"
        ],
        "tags": [
          "dosage"
        ],
        "source_note": null,
        "reasoning": null,
        "gold": {
          "dose_per_dose_mg": 810,
          "doses_per_day": 2,
          "total_daily_mg": 1620,
          "calc_rule": "90 mg/kg/day divided q12h",
          "max_daily_mg": 4000,
          "volume_per_dose_mL": 10.125,
          "rounding": {
            "to": "10 mL per dose",
            "basis": "80 mg/mL (400 mg/5 mL)"
          },
          "renal_adjustment": "none if normal renal function",
          "hepatic_adjustment": "none specified",
          "contraindications": [],
          "interactions": [],
          "recency_risk": false,
          "citations": [
            "lexi-amoxicillin-2018#dosage",
            "lexi-amoxicillin-2018#peds"
          ]
        },
        "oracle_context": [
          {
            "chunk_id": "lexi-amoxicillin-2018#dosage",
            "role": "support",
            "text": "Pediatric AOM first-line: amoxicillin 80–90 mg/kg/day PO divided q12h for 5–10 days; typical max daily dose ~4,000 mg."
          },
          {
            "chunk_id": "lexi-amoxicillin-2018#peds",
            "role": "support",
            "text": "Amoxicillin oral suspension 400 mg/5 mL = 80 mg/mL; use oral syringe; rounding to practical mL is acceptable."
          },
          {
            "chunk_id": "lexi-amoxicillin-2018#adult-sinusitis",
            "role": "distractor",
            "text": "Adult acute bacterial sinusitis regimens (e.g., 500 mg TID or 875 mg BID) differ from pediatric AOM dosing."
          }
        ],
        "judge_metadata": {
          "allowed_chunk_ids": [
            "lexi-amoxicillin-2018#dosage",
            "lexi-amoxicillin-2018#peds"
          ],
          "disallowed_chunk_ids": [
            "lexi-amoxicillin-2018#adult-sinusitis"
          ]
        }
      },
      "generated_answer": "{\n  \"dose_per_dose_mg\": 810,\n  \"volume_per_dose_mL\": 10.1,\n  \"frequency\": \"q12h\",\n  \"max_daily_mg\": 4000,\n  \"rounding\": \"rounding to practical mL is acceptable\",\n  \"calc_rule\": \"High-dose 80-90 mg/kg/day regimen; BID (q12h) frequency; Per-dose dose calculated as (18 kg * 80 mg/kg) / 5 mL (80 mg/mL); rounding to 10 mL OK; Max daily dose acknowledged\",\n  \"citations\": [\"lexi-amoxicillin-2018#dosage\"],\n  \"notes\": \"Uses high-dose 80-90 mg/kg/day regimen for pediatric AOM; BID (q12h) frequency; Per-dose ≈810 mg for 18 kg; Volume ≈10.1 mL",
      "expected_answer": "Amoxicillin 90 mg/kg/day divided q12h → 810 mg per dose (≈10.1 mL of 400 mg/5 mL), round to 10 mL per dose; max 4 g/day.",
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 0.5,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "precision_at_k": {
          "1": 1.0,
          "3": 0.6666666666666666,
          "5": 0.6666666666666666,
          "10": 0.6666666666666666,
          "20": 0.6666666666666666
        },
        "mean_reciprocal_rank": 1.0,
        "average_precision": 1.0,
        "ndcg_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "essential_recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "first_relevant_rank": 1,
        "total_relevant": 2,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.012665832537721989,
        "rouge_1_f1": 0.3934426229508196,
        "rouge_2_f1": 0.21666666666666665,
        "rouge_l_f1": 0.26229508196721313,
        "semantic_similarity": 0.8131217956542969,
        "key_points_covered": 0.5714285714285714,
        "key_points_found": [
          "Uses high-dose 80–90 mg/kg/day regimen",
          "BID (q12h) frequency",
          "Per-dose ≈810 mg for 18 kg",
          "Volume ≈10.1 mL from 400 mg/5 mL (80 mg/mL); rounding to 10 mL OK"
        ],
        "key_points_missing": [
          "Max daily 4 g acknowledged",
          "No renal adjustment if normal function",
          "Cites pediatric dosage section"
        ],
        "answer_length": 70,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "retrieval_results": [
        {
          "chunk_id": "lexi-amoxicillin-2018#dosage",
          "score": 0.0,
          "rank": 1
        },
        {
          "chunk_id": "lexi-amoxicillin-2018#peds",
          "score": 0.0,
          "rank": 2
        },
        {
          "chunk_id": "lexi-amoxicillin-2018#adult-sinusitis",
          "score": 0.0,
          "rank": 3
        }
      ],
      "context_chunks": [
        {
          "chunk_id": "lexi-amoxicillin-2018#dosage",
          "role": "support",
          "text": "Pediatric AOM first-line: amoxicillin 80–90 mg/kg/day PO divided q12h for 5–10 days; typical max daily dose ~4,000 mg."
        },
        {
          "chunk_id": "lexi-amoxicillin-2018#peds",
          "role": "support",
          "text": "Amoxicillin oral suspension 400 mg/5 mL = 80 mg/mL; use oral syringe; rounding to practical mL is acceptable."
        },
        {
          "chunk_id": "lexi-amoxicillin-2018#adult-sinusitis",
          "role": "distractor",
          "text": "Adult acute bacterial sinusitis regimens (e.g., 500 mg TID or 875 mg BID) differ from pediatric AOM dosing."
        }
      ],
      "failure_analysis": {
        "question_id": "q001",
        "question": "5-year-old (18 kg) with acute otitis media. What is the amoxicillin dose and volume using 400 mg/5 mL suspension?",
        "failure_types": [
          "qa_incomplete"
        ],
        "retrieved_chunks": [
          {
            "chunk_id": "lexi-amoxicillin-2018#dosage",
            "score": 0.0,
            "rank": 1
          },
          {
            "chunk_id": "lexi-amoxicillin-2018#peds",
            "score": 0.0,
            "rank": 2
          },
          {
            "chunk_id": "lexi-amoxicillin-2018#adult-sinusitis",
            "score": 0.0,
            "rank": 3
          }
        ],
        "relevant_chunks_found": [
          "lexi-amoxicillin-2018#dosage",
          "lexi-amoxicillin-2018#peds"
        ],
        "essential_chunks_missed": [],
        "generated_answer": "{\n  \"dose_per_dose_mg\": 810,\n  \"volume_per_dose_mL\": 10.1,\n  \"frequency\": \"q12h\",\n  \"max_daily_mg\": 4000,\n  \"rounding\": \"rounding to practical mL is acceptable\",\n  \"calc_rule\": \"High-dose 80-90 mg/kg/day regimen; BID (q12h) frequency; Per-dose dose calculated as (18 kg * 80 mg/kg) / 5 mL (80 mg/mL); rounding to 10 mL OK; Max daily dose acknowledged\",\n  \"citations\": [\"lexi-amoxicillin-2018#dosage\"],\n  \"notes\": \"Uses high-dose 80-90 mg/kg/day regimen for pediatric AOM; BID (q12h) frequency; Per-dose ≈810 mg for 18 kg; Volume ≈10.1 mL",
        "expected_answer": "Amoxicillin 90 mg/kg/day divided q12h → 810 mg per dose (≈10.1 mL of 400 mg/5 mL), round to 10 mL per dose; max 4 g/day.",
        "key_points_missing": [
          "Max daily 4 g acknowledged",
          "No renal adjustment if normal function",
          "Cites pediatric dosage section"
        ],
        "retrieval_metrics": {
          "recall_at_k": {
            "1": 0.5,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "precision_at_k": {
            "1": 1.0,
            "3": 0.6666666666666666,
            "5": 0.6666666666666666,
            "10": 0.6666666666666666,
            "20": 0.6666666666666666
          },
          "mean_reciprocal_rank": 1.0,
          "average_precision": 1.0,
          "ndcg_at_k": {
            "1": 1.0,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "essential_recall_at_k": {
            "1": 1.0,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "first_relevant_rank": 1,
          "total_relevant": 2,
          "total_essential": 1
        },
        "qa_metrics": {
          "bleu_score": 0.012665832537721989,
          "rouge_1_f1": 0.3934426229508196,
          "rouge_2_f1": 0.21666666666666665,
          "rouge_l_f1": 0.26229508196721313,
          "semantic_similarity": 0.8131217956542969,
          "key_points_covered": 0.5714285714285714,
          "key_points_found": [
            "Uses high-dose 80–90 mg/kg/day regimen",
            "BID (q12h) frequency",
            "Per-dose ≈810 mg for 18 kg",
            "Volume ≈10.1 mL from 400 mg/5 mL (80 mg/mL); rounding to 10 mL OK"
          ],
          "key_points_missing": [
            "Max daily 4 g acknowledged",
            "No renal adjustment if normal function",
            "Cites pediatric dosage section"
          ],
          "answer_length": 70,
          "has_answer": true,
          "factual_accuracy": null,
          "helpfulness": null
        },
        "root_cause": "qa_system",
        "severity": "medium",
        "notes": null
      }
    },
    {
      "question_id": "q002",
      "question": {
        "id": "q002",
        "question": "12 kg child with fever: acetaminophen dose and volume using 160 mg/5 mL?",
        "question_type": "dosage",
        "difficulty": "medium",
        "expected_answer": "Acetaminophen 15 mg/kg/dose q6h (range 10–15 mg/kg q4–6h) → 180 mg per dose ≈5.6 mL of 160 mg/5 mL; max 75 mg/kg/day (900 mg), and ≤4 g absolute.",
        "answer_key_points": [
          "Per-dose 15 mg/kg used",
          "q4–6h acceptable; target q6h in calc",
          "180 mg per dose for 12 kg",
          "Volume ≈5.625 mL from 32 mg/mL",
          "Daily max 75 mg/kg/day and ≤4 g",
          "Pediatric dosing section cited"
        ],
        "relevant_chunks": [
          {
            "chunk_id": "lexi-acetaminophen-2018#peds-dosing",
            "relevance_score": 1.0,
            "is_essential": true,
            "note": null
          },
          {
            "chunk_id": "lexi-acetaminophen-2018#max",
            "relevance_score": 1.0,
            "is_essential": false,
            "note": null
          }
        ],
        "drug_names": [
          "acetaminophen"
        ],
        "tags": [
          "dosage"
        ],
        "source_note": null,
        "reasoning": null,
        "gold": {
          "dose_per_dose_mg": 180,
          "doses_per_day": 4,
          "total_daily_mg": 720,
          "calc_rule": "15 mg/kg/dose q6h (10–15 mg/kg q4–6h acceptable)",
          "max_daily_mg": 900,
          "volume_per_dose_mL": 5.625,
          "rounding": {
            "to": "5.6 mL",
            "basis": "32 mg/mL (160 mg/5 mL)"
          },
          "renal_adjustment": "none for standard antipyresis",
          "hepatic_adjustment": "use caution in hepatic impairment",
          "contraindications": [],
          "interactions": [],
          "recency_risk": false,
          "citations": [
            "lexi-acetaminophen-2018#peds-dosing",
            "lexi-acetaminophen-2018#max"
          ]
        },
        "oracle_context": [
          {
            "chunk_id": "lexi-acetaminophen-2018#peds-dosing",
            "role": "support",
            "text": "Acetaminophen 10–15 mg/kg/dose PO q4–6h PRN fever/pain; do not exceed 75 mg/kg/day or 4,000 mg/day; ~5 doses/24h."
          },
          {
            "chunk_id": "lexi-acetaminophen-2018#max",
            "role": "support",
            "text": "Common liquid: 160 mg/5 mL (32 mg/mL). Use weight-based dosing and state per-dose mL."
          },
          {
            "chunk_id": "lexi-acetaminophen-2018#rectal",
            "role": "distractor",
            "text": "Rectal suppository dosing differs from oral liquids and is not used for this calculation."
          }
        ],
        "judge_metadata": {
          "allowed_chunk_ids": [
            "lexi-acetaminophen-2018#peds-dosing",
            "lexi-acetaminophen-2018#max"
          ],
          "disallowed_chunk_ids": [
            "lexi-acetaminophen-2018#rectal"
          ]
        }
      },
      "generated_answer": "{\n  \"dose_per_dose_mg\": 180,\n  \"volume_per_dose_mL\": 5.625,\n  \"frequency\": \"q6h\",\n  \"max_daily_mg\": 1440,\n  \"max_daily_mL\": null,\n  \"rounding\": \"rounded to one decimal\",\n  \"calc_rule\": \"15 mg/kg per dose, q4-6h, target q6h, 32 mg/mL\",\n  \"citations\": [\"lexi-acetaminophen-2018#peds-dosing\", \"lexi-acetaminophen-2018#max\"],\n  \"notes\": \"Pediatric dosing; liquid form\"\n}",
      "expected_answer": "Acetaminophen 15 mg/kg/dose q6h (range 10–15 mg/kg q4–6h) → 180 mg per dose ≈5.6 mL of 160 mg/5 mL; max 75 mg/kg/day (900 mg), and ≤4 g absolute.",
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 0.5,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "precision_at_k": {
          "1": 1.0,
          "3": 0.6666666666666666,
          "5": 0.6666666666666666,
          "10": 0.6666666666666666,
          "20": 0.6666666666666666
        },
        "mean_reciprocal_rank": 1.0,
        "average_precision": 1.0,
        "ndcg_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "essential_recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "first_relevant_rank": 1,
        "total_relevant": 2,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.00598648581729222,
        "rouge_1_f1": 0.3956043956043956,
        "rouge_2_f1": 0.0898876404494382,
        "rouge_l_f1": 0.2417582417582418,
        "semantic_similarity": 0.6589660048484802,
        "key_points_covered": 0.0,
        "key_points_found": [],
        "key_points_missing": [
          "Per-dose 15 mg/kg used",
          "q4–6h acceptable; target q6h in calc",
          "180 mg per dose for 12 kg",
          "Volume ≈5.625 mL from 32 mg/mL",
          "Daily max 75 mg/kg/day and ≤4 g",
          "Pediatric dosing section cited"
        ],
        "answer_length": 35,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "retrieval_results": [
        {
          "chunk_id": "lexi-acetaminophen-2018#peds-dosing",
          "score": 0.0,
          "rank": 1
        },
        {
          "chunk_id": "lexi-acetaminophen-2018#max",
          "score": 0.0,
          "rank": 2
        },
        {
          "chunk_id": "lexi-acetaminophen-2018#rectal",
          "score": 0.0,
          "rank": 3
        }
      ],
      "context_chunks": [
        {
          "chunk_id": "lexi-acetaminophen-2018#peds-dosing",
          "role": "support",
          "text": "Acetaminophen 10–15 mg/kg/dose PO q4–6h PRN fever/pain; do not exceed 75 mg/kg/day or 4,000 mg/day; ~5 doses/24h."
        },
        {
          "chunk_id": "lexi-acetaminophen-2018#max",
          "role": "support",
          "text": "Common liquid: 160 mg/5 mL (32 mg/mL). Use weight-based dosing and state per-dose mL."
        },
        {
          "chunk_id": "lexi-acetaminophen-2018#rectal",
          "role": "distractor",
          "text": "Rectal suppository dosing differs from oral liquids and is not used for this calculation."
        }
      ],
      "failure_analysis": {
        "question_id": "q002",
        "question": "12 kg child with fever: acetaminophen dose and volume using 160 mg/5 mL?",
        "failure_types": [
          "qa_incorrect",
          "qa_incomplete"
        ],
        "retrieved_chunks": [
          {
            "chunk_id": "lexi-acetaminophen-2018#peds-dosing",
            "score": 0.0,
            "rank": 1
          },
          {
            "chunk_id": "lexi-acetaminophen-2018#max",
            "score": 0.0,
            "rank": 2
          },
          {
            "chunk_id": "lexi-acetaminophen-2018#rectal",
            "score": 0.0,
            "rank": 3
          }
        ],
        "relevant_chunks_found": [
          "lexi-acetaminophen-2018#max",
          "lexi-acetaminophen-2018#peds-dosing"
        ],
        "essential_chunks_missed": [],
        "generated_answer": "{\n  \"dose_per_dose_mg\": 180,\n  \"volume_per_dose_mL\": 5.625,\n  \"frequency\": \"q6h\",\n  \"max_daily_mg\": 1440,\n  \"max_daily_mL\": null,\n  \"rounding\": \"rounded to one decimal\",\n  \"calc_rule\": \"15 mg/kg per dose, q4-6h, target q6h, 32 mg/mL\",\n  \"citations\": [\"lexi-acetaminophen-2018#peds-dosing\", \"lexi-acetaminophen-2018#max\"],\n  \"notes\": \"Pediatric dosing; liquid form\"\n}",
        "expected_answer": "Acetaminophen 15 mg/kg/dose q6h (range 10–15 mg/kg q4–6h) → 180 mg per dose ≈5.6 mL of 160 mg/5 mL; max 75 mg/kg/day (900 mg), and ≤4 g absolute.",
        "key_points_missing": [
          "Per-dose 15 mg/kg used",
          "q4–6h acceptable; target q6h in calc",
          "180 mg per dose for 12 kg",
          "Volume ≈5.625 mL from 32 mg/mL",
          "Daily max 75 mg/kg/day and ≤4 g",
          "Pediatric dosing section cited"
        ],
        "retrieval_metrics": {
          "recall_at_k": {
            "1": 0.5,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "precision_at_k": {
            "1": 1.0,
            "3": 0.6666666666666666,
            "5": 0.6666666666666666,
            "10": 0.6666666666666666,
            "20": 0.6666666666666666
          },
          "mean_reciprocal_rank": 1.0,
          "average_precision": 1.0,
          "ndcg_at_k": {
            "1": 1.0,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "essential_recall_at_k": {
            "1": 1.0,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "first_relevant_rank": 1,
          "total_relevant": 2,
          "total_essential": 1
        },
        "qa_metrics": {
          "bleu_score": 0.00598648581729222,
          "rouge_1_f1": 0.3956043956043956,
          "rouge_2_f1": 0.0898876404494382,
          "rouge_l_f1": 0.2417582417582418,
          "semantic_similarity": 0.6589660048484802,
          "key_points_covered": 0.0,
          "key_points_found": [],
          "key_points_missing": [
            "Per-dose 15 mg/kg used",
            "q4–6h acceptable; target q6h in calc",
            "180 mg per dose for 12 kg",
            "Volume ≈5.625 mL from 32 mg/mL",
            "Daily max 75 mg/kg/day and ≤4 g",
            "Pediatric dosing section cited"
          ],
          "answer_length": 35,
          "has_answer": true,
          "factual_accuracy": null,
          "helpfulness": null
        },
        "root_cause": "qa_system",
        "severity": "high",
        "notes": null
      }
    },
    {
      "question_id": "q003",
      "question": {
        "id": "q003",
        "question": "12 kg child with fever: ibuprofen dose and volume using 100 mg/5 mL?",
        "question_type": "dosage",
        "difficulty": "medium",
        "expected_answer": "Ibuprofen 10 mg/kg/dose q6–8h → 120 mg per dose (6 mL of 100 mg/5 mL); max 40 mg/kg/day (480 mg). Avoid if <6 months or dehydrated/renal issues.",
        "answer_key_points": [
          "10 mg/kg per dose",
          "q6–8h frequency",
          "120 mg per dose for 12 kg",
          "6 mL at 20 mg/mL",
          "Max 40 mg/kg/day (480 mg)",
          "Contraindication: <6 months; caution renal/dehydration"
        ],
        "relevant_chunks": [
          {
            "chunk_id": "lexi-ibuprofen-2018#peds-dosing",
            "relevance_score": 1.0,
            "is_essential": true,
            "note": null
          },
          {
            "chunk_id": "lexi-ibuprofen-2018#max",
            "relevance_score": 1.0,
            "is_essential": false,
            "note": null
          }
        ],
        "drug_names": [
          "ibuprofen"
        ],
        "tags": [
          "dosage"
        ],
        "source_note": null,
        "reasoning": null,
        "gold": {
          "dose_per_dose_mg": 120,
          "doses_per_day": 4,
          "total_daily_mg": 480,
          "calc_rule": "10 mg/kg/dose q6–8h; max 40 mg/kg/day",
          "max_daily_mg": 480,
          "volume_per_dose_mL": 6.0,
          "rounding": {
            "to": "6 mL",
            "basis": "20 mg/mL (100 mg/5 mL)"
          },
          "renal_adjustment": "avoid in significant renal impairment/dehydration",
          "hepatic_adjustment": "use caution",
          "contraindications": [
            "<6 months age",
            "active GI bleed"
          ],
          "interactions": [],
          "recency_risk": false,
          "citations": [
            "lexi-ibuprofen-2018#peds-dosing",
            "lexi-ibuprofen-2018#max"
          ]
        },
        "oracle_context": [
          {
            "chunk_id": "lexi-ibuprofen-2018#peds-dosing",
            "role": "support",
            "text": "Ibuprofen 10 mg/kg/dose PO q6–8h PRN; maximum 40 mg/kg/day; avoid in dehydration or significant renal risk."
          },
          {
            "chunk_id": "lexi-ibuprofen-2018#max",
            "role": "support",
            "text": "Oral suspension 100 mg/5 mL (20 mg/mL); compute per-dose mL from weight-based mg."
          },
          {
            "chunk_id": "lexi-ibuprofen-2018#adult-capsules",
            "role": "distractor",
            "text": "Adult OTC capsule labeling (200 mg) is not applicable to pediatric suspension dosing."
          }
        ],
        "judge_metadata": {
          "allowed_chunk_ids": [
            "lexi-ibuprofen-2018#peds-dosing",
            "lexi-ibuprofen-2018#max"
          ],
          "disallowed_chunk_ids": [
            "lexi-ibuprofen-2018#adult-capsules"
          ]
        }
      },
      "generated_answer": "{\n  \"dose_per_dose_mg\": 120,\n  \"volume_per_dose_mL\": 6.0,\n  \"frequency\": \"q6-8h\",\n  \"max_daily_mg\": 480,\n  \"rounding\": \"round to nearest 0.1 mL\",\n  \"calc_rule\": \"10 mg/kg per dose, maximum 40 mg/kg/day\",\n  \"citations\": [\"lexi-ibuprofen-2018#peds-dosing\", \"lexi-ibuprofen-2018#max\"],\n  \"notes\": \"12 kg child with fever: 120 mg ibuprofen per dose (6 mL of 100 mg/5 mL suspension), q6-8h; maximum daily dose 480 mg; contraindicated in children under 6 months and use with caution in renal/dehydration risk\"\n}",
      "expected_answer": "Ibuprofen 10 mg/kg/dose q6–8h → 120 mg per dose (6 mL of 100 mg/5 mL); max 40 mg/kg/day (480 mg). Avoid if <6 months or dehydrated/renal issues.",
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 0.5,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "precision_at_k": {
          "1": 1.0,
          "3": 0.6666666666666666,
          "5": 0.6666666666666666,
          "10": 0.6666666666666666,
          "20": 0.6666666666666666
        },
        "mean_reciprocal_rank": 1.0,
        "average_precision": 1.0,
        "ndcg_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "essential_recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "first_relevant_rank": 1,
        "total_relevant": 2,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.0858745369038274,
        "rouge_1_f1": 0.48333333333333334,
        "rouge_2_f1": 0.28813559322033894,
        "rouge_l_f1": 0.3333333333333333,
        "semantic_similarity": 0.7715703248977661,
        "key_points_covered": 0.6666666666666666,
        "key_points_found": [
          "10 mg/kg per dose",
          "120 mg per dose for 12 kg",
          "Max 40 mg/kg/day (480 mg)",
          "Contraindication: <6 months; caution renal/dehydration"
        ],
        "key_points_missing": [
          "q6–8h frequency",
          "6 mL at 20 mg/mL"
        ],
        "answer_length": 64,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "retrieval_results": [
        {
          "chunk_id": "lexi-ibuprofen-2018#peds-dosing",
          "score": 0.0,
          "rank": 1
        },
        {
          "chunk_id": "lexi-ibuprofen-2018#max",
          "score": 0.0,
          "rank": 2
        },
        {
          "chunk_id": "lexi-ibuprofen-2018#adult-capsules",
          "score": 0.0,
          "rank": 3
        }
      ],
      "context_chunks": [
        {
          "chunk_id": "lexi-ibuprofen-2018#peds-dosing",
          "role": "support",
          "text": "Ibuprofen 10 mg/kg/dose PO q6–8h PRN; maximum 40 mg/kg/day; avoid in dehydration or significant renal risk."
        },
        {
          "chunk_id": "lexi-ibuprofen-2018#max",
          "role": "support",
          "text": "Oral suspension 100 mg/5 mL (20 mg/mL); compute per-dose mL from weight-based mg."
        },
        {
          "chunk_id": "lexi-ibuprofen-2018#adult-capsules",
          "role": "distractor",
          "text": "Adult OTC capsule labeling (200 mg) is not applicable to pediatric suspension dosing."
        }
      ],
      "failure_analysis": {
        "question_id": "q003",
        "question": "12 kg child with fever: ibuprofen dose and volume using 100 mg/5 mL?",
        "failure_types": [
          "qa_incomplete"
        ],
        "retrieved_chunks": [
          {
            "chunk_id": "lexi-ibuprofen-2018#peds-dosing",
            "score": 0.0,
            "rank": 1
          },
          {
            "chunk_id": "lexi-ibuprofen-2018#max",
            "score": 0.0,
            "rank": 2
          },
          {
            "chunk_id": "lexi-ibuprofen-2018#adult-capsules",
            "score": 0.0,
            "rank": 3
          }
        ],
        "relevant_chunks_found": [
          "lexi-ibuprofen-2018#max",
          "lexi-ibuprofen-2018#peds-dosing"
        ],
        "essential_chunks_missed": [],
        "generated_answer": "{\n  \"dose_per_dose_mg\": 120,\n  \"volume_per_dose_mL\": 6.0,\n  \"frequency\": \"q6-8h\",\n  \"max_daily_mg\": 480,\n  \"rounding\": \"round to nearest 0.1 mL\",\n  \"calc_rule\": \"10 mg/kg per dose, maximum 40 mg/kg/day\",\n  \"citations\": [\"lexi-ibuprofen-2018#peds-dosing\", \"lexi-ibuprofen-2018#max\"],\n  \"notes\": \"12 kg child with fever: 120 mg ibuprofen per dose (6 mL of 100 mg/5 mL suspension), q6-8h; maximum daily dose 480 mg; contraindicated in children under 6 months and use with caution in renal/dehydration risk\"\n}",
        "expected_answer": "Ibuprofen 10 mg/kg/dose q6–8h → 120 mg per dose (6 mL of 100 mg/5 mL); max 40 mg/kg/day (480 mg). Avoid if <6 months or dehydrated/renal issues.",
        "key_points_missing": [
          "q6–8h frequency",
          "6 mL at 20 mg/mL"
        ],
        "retrieval_metrics": {
          "recall_at_k": {
            "1": 0.5,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "precision_at_k": {
            "1": 1.0,
            "3": 0.6666666666666666,
            "5": 0.6666666666666666,
            "10": 0.6666666666666666,
            "20": 0.6666666666666666
          },
          "mean_reciprocal_rank": 1.0,
          "average_precision": 1.0,
          "ndcg_at_k": {
            "1": 1.0,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "essential_recall_at_k": {
            "1": 1.0,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "first_relevant_rank": 1,
          "total_relevant": 2,
          "total_essential": 1
        },
        "qa_metrics": {
          "bleu_score": 0.0858745369038274,
          "rouge_1_f1": 0.48333333333333334,
          "rouge_2_f1": 0.28813559322033894,
          "rouge_l_f1": 0.3333333333333333,
          "semantic_similarity": 0.7715703248977661,
          "key_points_covered": 0.6666666666666666,
          "key_points_found": [
            "10 mg/kg per dose",
            "120 mg per dose for 12 kg",
            "Max 40 mg/kg/day (480 mg)",
            "Contraindication: <6 months; caution renal/dehydration"
          ],
          "key_points_missing": [
            "q6–8h frequency",
            "6 mL at 20 mg/mL"
          ],
          "answer_length": 64,
          "has_answer": true,
          "factual_accuracy": null,
          "helpfulness": null
        },
        "root_cause": "qa_system",
        "severity": "medium",
        "notes": null
      }
    },
    {
      "question_id": "q004",
      "question": {
        "id": "q004",
        "question": "Elderly patient with nonvalvular AF: 82 years, 58 kg, SCr 1.6 mg/dL. What apixaban dose?",
        "question_type": "dosage",
        "difficulty": "medium",
        "expected_answer": "Apixaban 2.5 mg BID (meets 2 of 3: age ≥80, weight ≤60 kg, SCr ≥1.5). Avoid with strong CYP3A4/P-gp inhibitors.",
        "answer_key_points": [
          "Dose reduction criteria (2 of 3)",
          "Final dose 2.5 mg BID",
          "Interaction caveat: strong CYP3A4/P-gp",
          "Hepatic impairment caution"
        ],
        "relevant_chunks": [
          {
            "chunk_id": "lexi-apixaban-2018#dosing-nvaf",
            "relevance_score": 1.0,
            "is_essential": true,
            "note": null
          },
          {
            "chunk_id": "lexi-apixaban-2018#ddi",
            "relevance_score": 1.0,
            "is_essential": false,
            "note": null
          }
        ],
        "drug_names": [
          "apixaban"
        ],
        "tags": [
          "dosage"
        ],
        "source_note": null,
        "reasoning": null,
        "gold": {
          "dose_per_dose_mg": 2.5,
          "doses_per_day": 2,
          "total_daily_mg": 5,
          "calc_rule": "If ≥2 of {age ≥80, weight ≤60 kg, SCr ≥1.5} → 2.5 mg BID",
          "max_daily_mg": 10,
          "renal_adjustment": "criteria-based reduction as above",
          "hepatic_adjustment": "avoid in severe hepatic impairment",
          "contraindications": [
            "active bleeding"
          ],
          "interactions": [
            {
              "drug": "strong CYP3A4/P-gp inhibitors",
              "severity": "major",
              "action": "avoid or reduce/monitor"
            }
          ],
          "recency_risk": false,
          "citations": [
            "lexi-apixaban-2018#dosing-nvaf",
            "lexi-apixaban-2018#ddi"
          ]
        },
        "oracle_context": [
          {
            "chunk_id": "lexi-apixaban-2018#dosing-nvaf",
            "role": "support",
            "text": "NVAF: apixaban 5 mg BID; reduce to 2.5 mg BID if the patient has ≥2 of: age ≥80 years, weight ≤60 kg, or serum creatinine ≥1.5 mg/dL."
          },
          {
            "chunk_id": "lexi-apixaban-2018#ddi",
            "role": "support",
            "text": "Avoid with strong dual CYP3A4/P-gp inhibitors/inducers; assess hepatic impairment."
          },
          {
            "chunk_id": "lexi-apixaban-2018#vte",
            "role": "distractor",
            "text": "VTE treatment: 10 mg BID x7 days then 5 mg BID—this regimen does not apply to NVAF dosing decisions."
          }
        ],
        "judge_metadata": {
          "allowed_chunk_ids": [
            "lexi-apixaban-2018#dosing-nvaf",
            "lexi-apixaban-2018#ddi"
          ],
          "disallowed_chunk_ids": [
            "lexi-apixaban-2018#vte"
          ]
        }
      },
      "generated_answer": "{\n  \"dose_per_dose_mg\": 2.5,\n  \"volume_per_dose_mL\": null,\n  \"frequency\": \"BID\",\n  \"max_daily_mg\": null,\n  \"rounding\": \"Not applicable (tablets)\",\n  \"calc_rule\": \"Dose reduction criteria: 2 of 3: age ≥80 years, weight ≤60 kg, or serum creatinine ≥1.5 mg/dL\",\n  \"citations\": [\"lexi-apixaban-2018#dosing-nvaf\"],\n  \"notes\": \"Avoid strong CYP3A4/P-gp inhibitors/inducers and assess hepatic impairment.\"",
      "expected_answer": "Apixaban 2.5 mg BID (meets 2 of 3: age ≥80, weight ≤60 kg, SCr ≥1.5). Avoid with strong CYP3A4/P-gp inhibitors.",
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 0.5,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "precision_at_k": {
          "1": 1.0,
          "3": 0.6666666666666666,
          "5": 0.6666666666666666,
          "10": 0.6666666666666666,
          "20": 0.6666666666666666
        },
        "mean_reciprocal_rank": 1.0,
        "average_precision": 1.0,
        "ndcg_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "essential_recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "first_relevant_rank": 1,
        "total_relevant": 2,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.09889276153808085,
        "rouge_1_f1": 0.4999999999999999,
        "rouge_2_f1": 0.3170731707317073,
        "rouge_l_f1": 0.45238095238095233,
        "semantic_similarity": 0.5738503932952881,
        "key_points_covered": 0.25,
        "key_points_found": [
          "Dose reduction criteria (2 of 3)"
        ],
        "key_points_missing": [
          "Final dose 2.5 mg BID",
          "Interaction caveat: strong CYP3A4/P-gp",
          "Hepatic impairment caution"
        ],
        "answer_length": 42,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "retrieval_results": [
        {
          "chunk_id": "lexi-apixaban-2018#dosing-nvaf",
          "score": 0.0,
          "rank": 1
        },
        {
          "chunk_id": "lexi-apixaban-2018#ddi",
          "score": 0.0,
          "rank": 2
        },
        {
          "chunk_id": "lexi-apixaban-2018#vte",
          "score": 0.0,
          "rank": 3
        }
      ],
      "context_chunks": [
        {
          "chunk_id": "lexi-apixaban-2018#dosing-nvaf",
          "role": "support",
          "text": "NVAF: apixaban 5 mg BID; reduce to 2.5 mg BID if the patient has ≥2 of: age ≥80 years, weight ≤60 kg, or serum creatinine ≥1.5 mg/dL."
        },
        {
          "chunk_id": "lexi-apixaban-2018#ddi",
          "role": "support",
          "text": "Avoid with strong dual CYP3A4/P-gp inhibitors/inducers; assess hepatic impairment."
        },
        {
          "chunk_id": "lexi-apixaban-2018#vte",
          "role": "distractor",
          "text": "VTE treatment: 10 mg BID x7 days then 5 mg BID—this regimen does not apply to NVAF dosing decisions."
        }
      ],
      "failure_analysis": {
        "question_id": "q004",
        "question": "Elderly patient with nonvalvular AF: 82 years, 58 kg, SCr 1.6 mg/dL. What apixaban dose?",
        "failure_types": [
          "qa_incorrect",
          "qa_incomplete",
          "e2e_low_quality"
        ],
        "retrieved_chunks": [
          {
            "chunk_id": "lexi-apixaban-2018#dosing-nvaf",
            "score": 0.0,
            "rank": 1
          },
          {
            "chunk_id": "lexi-apixaban-2018#ddi",
            "score": 0.0,
            "rank": 2
          },
          {
            "chunk_id": "lexi-apixaban-2018#vte",
            "score": 0.0,
            "rank": 3
          }
        ],
        "relevant_chunks_found": [
          "lexi-apixaban-2018#ddi",
          "lexi-apixaban-2018#dosing-nvaf"
        ],
        "essential_chunks_missed": [],
        "generated_answer": "{\n  \"dose_per_dose_mg\": 2.5,\n  \"volume_per_dose_mL\": null,\n  \"frequency\": \"BID\",\n  \"max_daily_mg\": null,\n  \"rounding\": \"Not applicable (tablets)\",\n  \"calc_rule\": \"Dose reduction criteria: 2 of 3: age ≥80 years, weight ≤60 kg, or serum creatinine ≥1.5 mg/dL\",\n  \"citations\": [\"lexi-apixaban-2018#dosing-nvaf\"],\n  \"notes\": \"Avoid strong CYP3A4/P-gp inhibitors/inducers and assess hepatic impairment.\"",
        "expected_answer": "Apixaban 2.5 mg BID (meets 2 of 3: age ≥80, weight ≤60 kg, SCr ≥1.5). Avoid with strong CYP3A4/P-gp inhibitors.",
        "key_points_missing": [
          "Final dose 2.5 mg BID",
          "Interaction caveat: strong CYP3A4/P-gp",
          "Hepatic impairment caution"
        ],
        "retrieval_metrics": {
          "recall_at_k": {
            "1": 0.5,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "precision_at_k": {
            "1": 1.0,
            "3": 0.6666666666666666,
            "5": 0.6666666666666666,
            "10": 0.6666666666666666,
            "20": 0.6666666666666666
          },
          "mean_reciprocal_rank": 1.0,
          "average_precision": 1.0,
          "ndcg_at_k": {
            "1": 1.0,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "essential_recall_at_k": {
            "1": 1.0,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "first_relevant_rank": 1,
          "total_relevant": 2,
          "total_essential": 1
        },
        "qa_metrics": {
          "bleu_score": 0.09889276153808085,
          "rouge_1_f1": 0.4999999999999999,
          "rouge_2_f1": 0.3170731707317073,
          "rouge_l_f1": 0.45238095238095233,
          "semantic_similarity": 0.5738503932952881,
          "key_points_covered": 0.25,
          "key_points_found": [
            "Dose reduction criteria (2 of 3)"
          ],
          "key_points_missing": [
            "Final dose 2.5 mg BID",
            "Interaction caveat: strong CYP3A4/P-gp",
            "Hepatic impairment caution"
          ],
          "answer_length": 42,
          "has_answer": true,
          "factual_accuracy": null,
          "helpfulness": null
        },
        "root_cause": "qa_system",
        "severity": "high",
        "notes": null
      }
    },
    {
      "question_id": "q005",
      "question": {
        "id": "q005",
        "question": "85 kg adult with acute DVT: What is the enoxaparin treatment dose (normal renal function)?",
        "question_type": "dosage",
        "difficulty": "medium",
        "expected_answer": "Enoxaparin 1 mg/kg SC q12h → 85 mg per dose (or 1.5 mg/kg once daily as alternative). If CrCl <30 mL/min: 1 mg/kg once daily.",
        "answer_key_points": [
          "1 mg/kg q12h primary regimen",
          "Alternative 1.5 mg/kg q24h",
          "Per-dose 85 mg for 85 kg",
          "Renal adjustment for CrCl <30"
        ],
        "relevant_chunks": [
          {
            "chunk_id": "lexi-enoxaparin-2018#dosing",
            "relevance_score": 1.0,
            "is_essential": true,
            "note": null
          },
          {
            "chunk_id": "lexi-enoxaparin-2018#renal",
            "relevance_score": 1.0,
            "is_essential": false,
            "note": null
          }
        ],
        "drug_names": [
          "enoxaparin"
        ],
        "tags": [
          "dosage"
        ],
        "source_note": null,
        "reasoning": null,
        "gold": {
          "dose_per_dose_mg": 85,
          "doses_per_day": 2,
          "total_daily_mg": 170,
          "calc_rule": "1 mg/kg q12h (or 1.5 mg/kg q24h alternative)",
          "max_daily_mg": null,
          "renal_adjustment": "CrCl <30: 1 mg/kg once daily",
          "hepatic_adjustment": "use caution",
          "contraindications": [
            "active major bleeding",
            "history of HIT (use alternative)"
          ],
          "interactions": [],
          "recency_risk": false,
          "citations": [
            "lexi-enoxaparin-2018#dosing",
            "lexi-enoxaparin-2018#renal"
          ]
        },
        "oracle_context": [
          {
            "chunk_id": "lexi-enoxaparin-2018#dosing",
            "role": "support",
            "text": "Acute DVT treatment (normal renal function): enoxaparin 1 mg/kg SC q12h (preferred) or 1.5 mg/kg SC once daily (alternative)."
          },
          {
            "chunk_id": "lexi-enoxaparin-2018#renal",
            "role": "support",
            "text": "If CrCl <30 mL/min, use 1 mg/kg SC once daily and monitor anti-Xa as indicated."
          },
          {
            "chunk_id": "lexi-enoxaparin-2018#prophylaxis",
            "role": "distractor",
            "text": "VTE prophylaxis doses (e.g., 40 mg SC daily) are not treatment doses and should not be used here."
          }
        ],
        "judge_metadata": {
          "allowed_chunk_ids": [
            "lexi-enoxaparin-2018#dosing",
            "lexi-enoxaparin-2018#renal"
          ],
          "disallowed_chunk_ids": [
            "lexi-enoxaparin-2018#prophylaxis"
          ]
        }
      },
      "generated_answer": "{\n  \"dose_per_dose_mg\": 85,\n  \"volume_per_dose_mL\": null,\n  \"frequency\": \"q12h\",\n  \"max_daily_mg\": null,\n  \"rounding\": \"Rounded to nearest whole number\",\n  \"calc_rule\": \"1 mg/kg q12h (primary regimen) or 1.5 mg/kg q24h (alternative), adjusted for renal function (CrCl <30: 1 mg/kg q24h)\",\n  \"citations\": [\"lexi-enoxaparin-2018#dosing\"],\n  \"notes\": \"Renal adjustment for CrCl <30 may be necessary\"\n}",
      "expected_answer": "Enoxaparin 1 mg/kg SC q12h → 85 mg per dose (or 1.5 mg/kg once daily as alternative). If CrCl <30 mL/min: 1 mg/kg once daily.",
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 0.5,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "precision_at_k": {
          "1": 1.0,
          "3": 0.6666666666666666,
          "5": 0.6666666666666666,
          "10": 0.6666666666666666,
          "20": 0.6666666666666666
        },
        "mean_reciprocal_rank": 1.0,
        "average_precision": 1.0,
        "ndcg_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "essential_recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "first_relevant_rank": 1,
        "total_relevant": 2,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.024771004662276757,
        "rouge_1_f1": 0.48888888888888893,
        "rouge_2_f1": 0.22727272727272724,
        "rouge_l_f1": 0.3333333333333333,
        "semantic_similarity": 0.7317655682563782,
        "key_points_covered": 0.75,
        "key_points_found": [
          "1 mg/kg q12h primary regimen",
          "Alternative 1.5 mg/kg q24h",
          "Renal adjustment for CrCl <30"
        ],
        "key_points_missing": [
          "Per-dose 85 mg for 85 kg"
        ],
        "answer_length": 47,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "retrieval_results": [
        {
          "chunk_id": "lexi-enoxaparin-2018#dosing",
          "score": 0.0,
          "rank": 1
        },
        {
          "chunk_id": "lexi-enoxaparin-2018#renal",
          "score": 0.0,
          "rank": 2
        },
        {
          "chunk_id": "lexi-enoxaparin-2018#prophylaxis",
          "score": 0.0,
          "rank": 3
        }
      ],
      "context_chunks": [
        {
          "chunk_id": "lexi-enoxaparin-2018#dosing",
          "role": "support",
          "text": "Acute DVT treatment (normal renal function): enoxaparin 1 mg/kg SC q12h (preferred) or 1.5 mg/kg SC once daily (alternative)."
        },
        {
          "chunk_id": "lexi-enoxaparin-2018#renal",
          "role": "support",
          "text": "If CrCl <30 mL/min, use 1 mg/kg SC once daily and monitor anti-Xa as indicated."
        },
        {
          "chunk_id": "lexi-enoxaparin-2018#prophylaxis",
          "role": "distractor",
          "text": "VTE prophylaxis doses (e.g., 40 mg SC daily) are not treatment doses and should not be used here."
        }
      ],
      "failure_analysis": {
        "question_id": "q005",
        "question": "85 kg adult with acute DVT: What is the enoxaparin treatment dose (normal renal function)?",
        "failure_types": [
          "qa_incomplete"
        ],
        "retrieved_chunks": [
          {
            "chunk_id": "lexi-enoxaparin-2018#dosing",
            "score": 0.0,
            "rank": 1
          },
          {
            "chunk_id": "lexi-enoxaparin-2018#renal",
            "score": 0.0,
            "rank": 2
          },
          {
            "chunk_id": "lexi-enoxaparin-2018#prophylaxis",
            "score": 0.0,
            "rank": 3
          }
        ],
        "relevant_chunks_found": [
          "lexi-enoxaparin-2018#dosing",
          "lexi-enoxaparin-2018#renal"
        ],
        "essential_chunks_missed": [],
        "generated_answer": "{\n  \"dose_per_dose_mg\": 85,\n  \"volume_per_dose_mL\": null,\n  \"frequency\": \"q12h\",\n  \"max_daily_mg\": null,\n  \"rounding\": \"Rounded to nearest whole number\",\n  \"calc_rule\": \"1 mg/kg q12h (primary regimen) or 1.5 mg/kg q24h (alternative), adjusted for renal function (CrCl <30: 1 mg/kg q24h)\",\n  \"citations\": [\"lexi-enoxaparin-2018#dosing\"],\n  \"notes\": \"Renal adjustment for CrCl <30 may be necessary\"\n}",
        "expected_answer": "Enoxaparin 1 mg/kg SC q12h → 85 mg per dose (or 1.5 mg/kg once daily as alternative). If CrCl <30 mL/min: 1 mg/kg once daily.",
        "key_points_missing": [
          "Per-dose 85 mg for 85 kg"
        ],
        "retrieval_metrics": {
          "recall_at_k": {
            "1": 0.5,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "precision_at_k": {
            "1": 1.0,
            "3": 0.6666666666666666,
            "5": 0.6666666666666666,
            "10": 0.6666666666666666,
            "20": 0.6666666666666666
          },
          "mean_reciprocal_rank": 1.0,
          "average_precision": 1.0,
          "ndcg_at_k": {
            "1": 1.0,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "essential_recall_at_k": {
            "1": 1.0,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "first_relevant_rank": 1,
          "total_relevant": 2,
          "total_essential": 1
        },
        "qa_metrics": {
          "bleu_score": 0.024771004662276757,
          "rouge_1_f1": 0.48888888888888893,
          "rouge_2_f1": 0.22727272727272724,
          "rouge_l_f1": 0.3333333333333333,
          "semantic_similarity": 0.7317655682563782,
          "key_points_covered": 0.75,
          "key_points_found": [
            "1 mg/kg q12h primary regimen",
            "Alternative 1.5 mg/kg q24h",
            "Renal adjustment for CrCl <30"
          ],
          "key_points_missing": [
            "Per-dose 85 mg for 85 kg"
          ],
          "answer_length": 47,
          "has_answer": true,
          "factual_accuracy": null,
          "helpfulness": null
        },
        "root_cause": "qa_system",
        "severity": "medium",
        "notes": null
      }
    },
    {
      "question_id": "q006",
      "question": {
        "id": "q006",
        "question": "Type 2 diabetes patient with eGFR 28 mL/min/1.73 m². Can we use metformin?",
        "question_type": "dosage",
        "difficulty": "medium",
        "expected_answer": "No—contraindicated at eGFR <30. If 30–45, generally avoid initiation; if continuing, reduce dose and monitor. Avoid in hepatic impairment.",
        "answer_key_points": [
          "Contraindicated if eGFR <30",
          "30–45: avoid initiation; if continuing, reduce & monitor",
          "Hepatic impairment: avoid (lactic acidosis risk)"
        ],
        "relevant_chunks": [
          {
            "chunk_id": "lexi-metformin-2018#renal",
            "relevance_score": 1.0,
            "is_essential": true,
            "note": null
          },
          {
            "chunk_id": "lexi-metformin-2018#contra",
            "relevance_score": 1.0,
            "is_essential": false,
            "note": null
          }
        ],
        "drug_names": [
          "metformin"
        ],
        "tags": [
          "dosage"
        ],
        "source_note": null,
        "reasoning": null,
        "gold": {
          "decision": "contraindicated",
          "calc_rule": "eGFR <30 → do not initiate/continue",
          "renal_adjustment": "eGFR 30–45: avoid initiation; reduce if continuing; monitor",
          "hepatic_adjustment": "avoid in hepatic impairment",
          "contraindications": [
            "eGFR <30",
            "acute/chronic metabolic acidosis"
          ],
          "interactions": [
            {
              "drug": "iodinated contrast",
              "severity": "major",
              "action": "hold around procedure per eGFR"
            }
          ],
          "recency_risk": false,
          "citations": [
            "lexi-metformin-2018#renal",
            "lexi-metformin-2018#contra"
          ]
        },
        "oracle_context": [
          {
            "chunk_id": "lexi-metformin-2018#renal",
            "role": "support",
            "text": "Metformin: contraindicated if eGFR <30 mL/min/1.73 m². At 30–45, generally avoid initiation; if continuing, reduce dose and monitor renal function."
          },
          {
            "chunk_id": "lexi-metformin-2018#contra",
            "role": "support",
            "text": "Avoid in hepatic impairment or conditions predisposing to lactic acidosis; manage iodinated contrast per eGFR."
          },
          {
            "chunk_id": "lexi-metformin-2018#old-crcl60",
            "role": "distractor",
            "text": "Older conservative thresholds (e.g., avoid if CrCl <60) are superseded by eGFR-based guidance."
          }
        ],
        "judge_metadata": {
          "allowed_chunk_ids": [
            "lexi-metformin-2018#renal",
            "lexi-metformin-2018#contra"
          ],
          "disallowed_chunk_ids": [
            "lexi-metformin-2018#old-crcl60"
          ]
        }
      },
      "generated_answer": "{\n  \"dose_per_dose_mg\": null,\n  \"volume_per_dose_mL\": null,\n  \"frequency\": null,\n  \"max_daily_mg\": null,\n  \"rounding\": \"Not applicable\",\n  \"calc_rule\": \"Contraindicated if eGFR <30, avoid initiation if 30-45, continue with dose reduction and monitoring\",\n  \"citations\": [\"lexi-metformin-2018#renal\"],\n  \"notes\": \"Metformin is contraindicated in eGFR <30 mL/min/1.73 m², and should be avoided in initiation for eGFR 30-45. If continued, dose reduction and monitoring of renal function is necessary.\"",
      "expected_answer": "No—contraindicated at eGFR <30. If 30–45, generally avoid initiation; if continuing, reduce dose and monitor. Avoid in hepatic impairment.",
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 0.5,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "precision_at_k": {
          "1": 1.0,
          "3": 0.6666666666666666,
          "5": 0.6666666666666666,
          "10": 0.6666666666666666,
          "20": 0.6666666666666666
        },
        "mean_reciprocal_rank": 1.0,
        "average_precision": 1.0,
        "ndcg_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "essential_recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "first_relevant_rank": 1,
        "total_relevant": 2,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.013195944411119548,
        "rouge_1_f1": 0.31578947368421056,
        "rouge_2_f1": 0.17204301075268816,
        "rouge_l_f1": 0.2736842105263158,
        "semantic_similarity": 0.6303442120552063,
        "key_points_covered": 0.3333333333333333,
        "key_points_found": [
          "Contraindicated if eGFR <30"
        ],
        "key_points_missing": [
          "30–45: avoid initiation; if continuing, reduce & monitor",
          "Hepatic impairment: avoid (lactic acidosis risk)"
        ],
        "answer_length": 58,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "retrieval_results": [
        {
          "chunk_id": "lexi-metformin-2018#renal",
          "score": 0.0,
          "rank": 1
        },
        {
          "chunk_id": "lexi-metformin-2018#contra",
          "score": 0.0,
          "rank": 2
        },
        {
          "chunk_id": "lexi-metformin-2018#old-crcl60",
          "score": 0.0,
          "rank": 3
        }
      ],
      "context_chunks": [
        {
          "chunk_id": "lexi-metformin-2018#renal",
          "role": "support",
          "text": "Metformin: contraindicated if eGFR <30 mL/min/1.73 m². At 30–45, generally avoid initiation; if continuing, reduce dose and monitor renal function."
        },
        {
          "chunk_id": "lexi-metformin-2018#contra",
          "role": "support",
          "text": "Avoid in hepatic impairment or conditions predisposing to lactic acidosis; manage iodinated contrast per eGFR."
        },
        {
          "chunk_id": "lexi-metformin-2018#old-crcl60",
          "role": "distractor",
          "text": "Older conservative thresholds (e.g., avoid if CrCl <60) are superseded by eGFR-based guidance."
        }
      ],
      "failure_analysis": {
        "question_id": "q006",
        "question": "Type 2 diabetes patient with eGFR 28 mL/min/1.73 m². Can we use metformin?",
        "failure_types": [
          "qa_incorrect",
          "qa_incomplete"
        ],
        "retrieved_chunks": [
          {
            "chunk_id": "lexi-metformin-2018#renal",
            "score": 0.0,
            "rank": 1
          },
          {
            "chunk_id": "lexi-metformin-2018#contra",
            "score": 0.0,
            "rank": 2
          },
          {
            "chunk_id": "lexi-metformin-2018#old-crcl60",
            "score": 0.0,
            "rank": 3
          }
        ],
        "relevant_chunks_found": [
          "lexi-metformin-2018#contra",
          "lexi-metformin-2018#renal"
        ],
        "essential_chunks_missed": [],
        "generated_answer": "{\n  \"dose_per_dose_mg\": null,\n  \"volume_per_dose_mL\": null,\n  \"frequency\": null,\n  \"max_daily_mg\": null,\n  \"rounding\": \"Not applicable\",\n  \"calc_rule\": \"Contraindicated if eGFR <30, avoid initiation if 30-45, continue with dose reduction and monitoring\",\n  \"citations\": [\"lexi-metformin-2018#renal\"],\n  \"notes\": \"Metformin is contraindicated in eGFR <30 mL/min/1.73 m², and should be avoided in initiation for eGFR 30-45. If continued, dose reduction and monitoring of renal function is necessary.\"",
        "expected_answer": "No—contraindicated at eGFR <30. If 30–45, generally avoid initiation; if continuing, reduce dose and monitor. Avoid in hepatic impairment.",
        "key_points_missing": [
          "30–45: avoid initiation; if continuing, reduce & monitor",
          "Hepatic impairment: avoid (lactic acidosis risk)"
        ],
        "retrieval_metrics": {
          "recall_at_k": {
            "1": 0.5,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "precision_at_k": {
            "1": 1.0,
            "3": 0.6666666666666666,
            "5": 0.6666666666666666,
            "10": 0.6666666666666666,
            "20": 0.6666666666666666
          },
          "mean_reciprocal_rank": 1.0,
          "average_precision": 1.0,
          "ndcg_at_k": {
            "1": 1.0,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "essential_recall_at_k": {
            "1": 1.0,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "first_relevant_rank": 1,
          "total_relevant": 2,
          "total_essential": 1
        },
        "qa_metrics": {
          "bleu_score": 0.013195944411119548,
          "rouge_1_f1": 0.31578947368421056,
          "rouge_2_f1": 0.17204301075268816,
          "rouge_l_f1": 0.2736842105263158,
          "semantic_similarity": 0.6303442120552063,
          "key_points_covered": 0.3333333333333333,
          "key_points_found": [
            "Contraindicated if eGFR <30"
          ],
          "key_points_missing": [
            "30–45: avoid initiation; if continuing, reduce & monitor",
            "Hepatic impairment: avoid (lactic acidosis risk)"
          ],
          "answer_length": 58,
          "has_answer": true,
          "factual_accuracy": null,
          "helpfulness": null
        },
        "root_cause": "qa_system",
        "severity": "high",
        "notes": null
      }
    },
    {
      "question_id": "q007",
      "question": {
        "id": "q007",
        "question": "Uncomplicated cystitis: Should we use nitrofurantoin if eGFR is 25?",
        "question_type": "dosage",
        "difficulty": "medium",
        "expected_answer": "Avoid nitrofurantoin when eGFR/CrCl <30 mL/min due to low urinary levels and toxicity risk.",
        "answer_key_points": [
          "Avoid if eGFR/CrCl <30",
          "Rationale: efficacy/toxicity",
          "List common contraindications where relevant"
        ],
        "relevant_chunks": [
          {
            "chunk_id": "lexi-nitrofurantoin-2018#renal",
            "relevance_score": 1.0,
            "is_essential": true,
            "note": null
          },
          {
            "chunk_id": "lexi-nitrofurantoin-2018#contra",
            "relevance_score": 1.0,
            "is_essential": false,
            "note": null
          }
        ],
        "drug_names": [
          "nitrofurantoin"
        ],
        "tags": [
          "dosage"
        ],
        "source_note": null,
        "reasoning": null,
        "gold": {
          "decision": "avoid",
          "calc_rule": "Avoid if eGFR/CrCl <30",
          "renal_adjustment": "not recommended below threshold",
          "hepatic_adjustment": "use caution",
          "contraindications": [
            "CrCl <30",
            "late-term pregnancy (at term)"
          ],
          "interactions": [],
          "recency_risk": false,
          "citations": [
            "lexi-nitrofurantoin-2018#renal",
            "lexi-nitrofurantoin-2018#contra"
          ]
        },
        "oracle_context": [
          {
            "chunk_id": "lexi-nitrofurantoin-2018#renal",
            "role": "support",
            "text": "Nitrofurantoin: avoid when eGFR/CrCl <30 mL/min due to inadequate urinary concentrations and increased toxicity risk."
          },
          {
            "chunk_id": "lexi-nitrofurantoin-2018#contra",
            "role": "support",
            "text": "Contraindications include late-term pregnancy (at term) and significant renal dysfunction."
          },
          {
            "chunk_id": "lexi-nitrofurantoin-2018#prophylaxis",
            "role": "distractor",
            "text": "Prophylaxis regimens (e.g., low-dose at bedtime) do not override renal cutoffs for acute cystitis treatment."
          }
        ],
        "judge_metadata": {
          "allowed_chunk_ids": [
            "lexi-nitrofurantoin-2018#renal",
            "lexi-nitrofurantoin-2018#contra"
          ],
          "disallowed_chunk_ids": [
            "lexi-nitrofurantoin-2018#prophylaxis"
          ]
        }
      },
      "generated_answer": "{\n  \"dose_per_dose_mg\": null,\n  \"volume_per_dose_mL\": null,\n  \"frequency\": null,\n  \"max_daily_mg\": null,\n  \"rounding\": \"Not applicable\",\n  \"calc_rule\": \"Avoid use if eGFR/CrCl <30 mL/min due to inadequate urinary concentrations and increased toxicity risk (lexi-nitrofurantoin-2018#renal)\",\n  \"citations\": [\"lexi-nitrofurantoin-2018#renal\"],\n  \"notes\": \"Avoid nitrofurantoin in eGFR/CrCl <30 mL/min due to efficacy and toxicity concerns. Common contraindications include significant renal dysfunction (lexi-nitrofurantoin-2018#contra).\"\n}",
      "expected_answer": "Avoid nitrofurantoin when eGFR/CrCl <30 mL/min due to low urinary levels and toxicity risk.",
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 0.5,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "precision_at_k": {
          "1": 1.0,
          "3": 0.6666666666666666,
          "5": 0.6666666666666666,
          "10": 0.6666666666666666,
          "20": 0.6666666666666666
        },
        "mean_reciprocal_rank": 1.0,
        "average_precision": 1.0,
        "ndcg_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "essential_recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "first_relevant_rank": 1,
        "total_relevant": 2,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.05634113296924294,
        "rouge_1_f1": 0.29545454545454547,
        "rouge_2_f1": 0.20930232558139536,
        "rouge_l_f1": 0.27272727272727276,
        "semantic_similarity": 0.8060358166694641,
        "key_points_covered": 0.3333333333333333,
        "key_points_found": [
          "Avoid if eGFR/CrCl <30"
        ],
        "key_points_missing": [
          "Rationale: efficacy/toxicity",
          "List common contraindications where relevant"
        ],
        "answer_length": 52,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "retrieval_results": [
        {
          "chunk_id": "lexi-nitrofurantoin-2018#renal",
          "score": 0.0,
          "rank": 1
        },
        {
          "chunk_id": "lexi-nitrofurantoin-2018#contra",
          "score": 0.0,
          "rank": 2
        },
        {
          "chunk_id": "lexi-nitrofurantoin-2018#prophylaxis",
          "score": 0.0,
          "rank": 3
        }
      ],
      "context_chunks": [
        {
          "chunk_id": "lexi-nitrofurantoin-2018#renal",
          "role": "support",
          "text": "Nitrofurantoin: avoid when eGFR/CrCl <30 mL/min due to inadequate urinary concentrations and increased toxicity risk."
        },
        {
          "chunk_id": "lexi-nitrofurantoin-2018#contra",
          "role": "support",
          "text": "Contraindications include late-term pregnancy (at term) and significant renal dysfunction."
        },
        {
          "chunk_id": "lexi-nitrofurantoin-2018#prophylaxis",
          "role": "distractor",
          "text": "Prophylaxis regimens (e.g., low-dose at bedtime) do not override renal cutoffs for acute cystitis treatment."
        }
      ],
      "failure_analysis": {
        "question_id": "q007",
        "question": "Uncomplicated cystitis: Should we use nitrofurantoin if eGFR is 25?",
        "failure_types": [
          "qa_incomplete"
        ],
        "retrieved_chunks": [
          {
            "chunk_id": "lexi-nitrofurantoin-2018#renal",
            "score": 0.0,
            "rank": 1
          },
          {
            "chunk_id": "lexi-nitrofurantoin-2018#contra",
            "score": 0.0,
            "rank": 2
          },
          {
            "chunk_id": "lexi-nitrofurantoin-2018#prophylaxis",
            "score": 0.0,
            "rank": 3
          }
        ],
        "relevant_chunks_found": [
          "lexi-nitrofurantoin-2018#contra",
          "lexi-nitrofurantoin-2018#renal"
        ],
        "essential_chunks_missed": [],
        "generated_answer": "{\n  \"dose_per_dose_mg\": null,\n  \"volume_per_dose_mL\": null,\n  \"frequency\": null,\n  \"max_daily_mg\": null,\n  \"rounding\": \"Not applicable\",\n  \"calc_rule\": \"Avoid use if eGFR/CrCl <30 mL/min due to inadequate urinary concentrations and increased toxicity risk (lexi-nitrofurantoin-2018#renal)\",\n  \"citations\": [\"lexi-nitrofurantoin-2018#renal\"],\n  \"notes\": \"Avoid nitrofurantoin in eGFR/CrCl <30 mL/min due to efficacy and toxicity concerns. Common contraindications include significant renal dysfunction (lexi-nitrofurantoin-2018#contra).\"\n}",
        "expected_answer": "Avoid nitrofurantoin when eGFR/CrCl <30 mL/min due to low urinary levels and toxicity risk.",
        "key_points_missing": [
          "Rationale: efficacy/toxicity",
          "List common contraindications where relevant"
        ],
        "retrieval_metrics": {
          "recall_at_k": {
            "1": 0.5,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "precision_at_k": {
            "1": 1.0,
            "3": 0.6666666666666666,
            "5": 0.6666666666666666,
            "10": 0.6666666666666666,
            "20": 0.6666666666666666
          },
          "mean_reciprocal_rank": 1.0,
          "average_precision": 1.0,
          "ndcg_at_k": {
            "1": 1.0,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "essential_recall_at_k": {
            "1": 1.0,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "first_relevant_rank": 1,
          "total_relevant": 2,
          "total_essential": 1
        },
        "qa_metrics": {
          "bleu_score": 0.05634113296924294,
          "rouge_1_f1": 0.29545454545454547,
          "rouge_2_f1": 0.20930232558139536,
          "rouge_l_f1": 0.27272727272727276,
          "semantic_similarity": 0.8060358166694641,
          "key_points_covered": 0.3333333333333333,
          "key_points_found": [
            "Avoid if eGFR/CrCl <30"
          ],
          "key_points_missing": [
            "Rationale: efficacy/toxicity",
            "List common contraindications where relevant"
          ],
          "answer_length": 52,
          "has_answer": true,
          "factual_accuracy": null,
          "helpfulness": null
        },
        "root_cause": "qa_system",
        "severity": "medium",
        "notes": null
      }
    },
    {
      "question_id": "q008",
      "question": {
        "id": "q008",
        "question": "Patient on warfarin needs TMP-SMX for UTI. Any interaction and what should we do?",
        "question_type": "interaction",
        "difficulty": "medium",
        "expected_answer": "Major interaction (CYP2C9 inhibition + gut flora). Avoid if possible; otherwise increase INR monitoring and reduce warfarin dose.",
        "answer_key_points": [
          "Mechanism: CYP2C9 inhibition + gut flora",
          "Severity: major",
          "Action: avoid or close INR monitoring with dose reduction"
        ],
        "relevant_chunks": [
          {
            "chunk_id": "lexi-warfarin-2018#ddi-tmp-smx",
            "relevance_score": 1.0,
            "is_essential": true,
            "note": null
          }
        ],
        "drug_names": [
          "warfarin"
        ],
        "tags": [
          "interaction"
        ],
        "source_note": null,
        "reasoning": null,
        "gold": {
          "interactions": [
            {
              "drug": "trimethoprim/sulfamethoxazole",
              "mechanism": "CYP2C9 inhibition + gut flora change",
              "severity": "major",
              "action": "avoid if possible; otherwise increase INR monitoring and reduce warfarin dose"
            }
          ],
          "contraindications": [],
          "recency_risk": false,
          "citations": [
            "lexi-warfarin-2018#ddi-tmp-smx"
          ]
        },
        "oracle_context": [
          {
            "chunk_id": "lexi-warfarin-2018#ddi-tmp-smx",
            "role": "support",
            "text": "TMP-SMX markedly increases warfarin effect via CYP2C9 inhibition and gut-flora changes; expect INR rise. Prefer alternatives; if used, reduce warfarin dose and increase INR monitoring."
          },
          {
            "chunk_id": "lexi-warfarin-2018#ddi-cephalexin",
            "role": "distractor",
            "text": "Cephalexin has minimal effect on warfarin relative to TMP-SMX; management differs."
          }
        ],
        "judge_metadata": {
          "allowed_chunk_ids": [
            "lexi-warfarin-2018#ddi-tmp-smx"
          ],
          "disallowed_chunk_ids": [
            "lexi-warfarin-2018#ddi-cephalexin"
          ]
        }
      },
      "generated_answer": "{\n  \"dose_per_dose_mg\": null,\n  \"volume_per_dose_mL\": null,\n  \"frequency\": \"q12h\",\n  \"max_daily_mg\": null,\n  \"rounding\": \"round to nearest 5mg\",\n  \"calc_rule\": \"Avoid TMP-SMX due to major interaction (CYP2C9 inhibition and gut flora changes), leading to increased INR. If used, reduce warfarin dose and increase INR monitoring.\",\n  \"citations\": [\"lexi-warfarin-2018#ddi-tmp-smx\"],\n  \"notes\": \"Avoid TMP-SMX with warfarin; close INR monitoring with dose reduction if used.\"\n}",
      "expected_answer": "Major interaction (CYP2C9 inhibition + gut flora). Avoid if possible; otherwise increase INR monitoring and reduce warfarin dose.",
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "precision_at_k": {
          "1": 1.0,
          "3": 0.5,
          "5": 0.5,
          "10": 0.5,
          "20": 0.5
        },
        "mean_reciprocal_rank": 1.0,
        "average_precision": 1.0,
        "ndcg_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "essential_recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "first_relevant_rank": 1,
        "total_relevant": 1,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.060594492461490825,
        "rouge_1_f1": 0.3448275862068966,
        "rouge_2_f1": 0.18823529411764708,
        "rouge_l_f1": 0.2758620689655173,
        "semantic_similarity": 0.6212816834449768,
        "key_points_covered": 0.6666666666666666,
        "key_points_found": [
          "Mechanism: CYP2C9 inhibition + gut flora",
          "Action: avoid or close INR monitoring with dose reduction"
        ],
        "key_points_missing": [
          "Severity: major"
        ],
        "answer_length": 56,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "retrieval_results": [
        {
          "chunk_id": "lexi-warfarin-2018#ddi-tmp-smx",
          "score": 0.0,
          "rank": 1
        },
        {
          "chunk_id": "lexi-warfarin-2018#ddi-cephalexin",
          "score": 0.0,
          "rank": 2
        }
      ],
      "context_chunks": [
        {
          "chunk_id": "lexi-warfarin-2018#ddi-tmp-smx",
          "role": "support",
          "text": "TMP-SMX markedly increases warfarin effect via CYP2C9 inhibition and gut-flora changes; expect INR rise. Prefer alternatives; if used, reduce warfarin dose and increase INR monitoring."
        },
        {
          "chunk_id": "lexi-warfarin-2018#ddi-cephalexin",
          "role": "distractor",
          "text": "Cephalexin has minimal effect on warfarin relative to TMP-SMX; management differs."
        }
      ],
      "failure_analysis": {
        "question_id": "q008",
        "question": "Patient on warfarin needs TMP-SMX for UTI. Any interaction and what should we do?",
        "failure_types": [
          "retrieval_irrelevant",
          "qa_incorrect",
          "qa_incomplete"
        ],
        "retrieved_chunks": [
          {
            "chunk_id": "lexi-warfarin-2018#ddi-tmp-smx",
            "score": 0.0,
            "rank": 1
          },
          {
            "chunk_id": "lexi-warfarin-2018#ddi-cephalexin",
            "score": 0.0,
            "rank": 2
          }
        ],
        "relevant_chunks_found": [
          "lexi-warfarin-2018#ddi-tmp-smx"
        ],
        "essential_chunks_missed": [],
        "generated_answer": "{\n  \"dose_per_dose_mg\": null,\n  \"volume_per_dose_mL\": null,\n  \"frequency\": \"q12h\",\n  \"max_daily_mg\": null,\n  \"rounding\": \"round to nearest 5mg\",\n  \"calc_rule\": \"Avoid TMP-SMX due to major interaction (CYP2C9 inhibition and gut flora changes), leading to increased INR. If used, reduce warfarin dose and increase INR monitoring.\",\n  \"citations\": [\"lexi-warfarin-2018#ddi-tmp-smx\"],\n  \"notes\": \"Avoid TMP-SMX with warfarin; close INR monitoring with dose reduction if used.\"\n}",
        "expected_answer": "Major interaction (CYP2C9 inhibition + gut flora). Avoid if possible; otherwise increase INR monitoring and reduce warfarin dose.",
        "key_points_missing": [
          "Severity: major"
        ],
        "retrieval_metrics": {
          "recall_at_k": {
            "1": 1.0,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "precision_at_k": {
            "1": 1.0,
            "3": 0.5,
            "5": 0.5,
            "10": 0.5,
            "20": 0.5
          },
          "mean_reciprocal_rank": 1.0,
          "average_precision": 1.0,
          "ndcg_at_k": {
            "1": 1.0,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "essential_recall_at_k": {
            "1": 1.0,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "first_relevant_rank": 1,
          "total_relevant": 1,
          "total_essential": 1
        },
        "qa_metrics": {
          "bleu_score": 0.060594492461490825,
          "rouge_1_f1": 0.3448275862068966,
          "rouge_2_f1": 0.18823529411764708,
          "rouge_l_f1": 0.2758620689655173,
          "semantic_similarity": 0.6212816834449768,
          "key_points_covered": 0.6666666666666666,
          "key_points_found": [
            "Mechanism: CYP2C9 inhibition + gut flora",
            "Action: avoid or close INR monitoring with dose reduction"
          ],
          "key_points_missing": [
            "Severity: major"
          ],
          "answer_length": 56,
          "has_answer": true,
          "factual_accuracy": null,
          "helpfulness": null
        },
        "root_cause": "both_systems",
        "severity": "high",
        "notes": null
      }
    },
    {
      "question_id": "q009",
      "question": {
        "id": "q009",
        "question": "Patient on atorvastatin needs clarithromycin. What’s the risk and action?",
        "question_type": "interaction",
        "difficulty": "medium",
        "expected_answer": "Major interaction (strong CYP3A4 inhibitor). Avoid coadministration; if unavoidable, hold atorvastatin or limit to the lowest dose and monitor for myopathy.",
        "answer_key_points": [
          "Mechanism: strong CYP3A4 inhibition",
          "Severity: major",
          "Action: avoid; if unavoidable hold or use lowest dose with monitoring"
        ],
        "relevant_chunks": [
          {
            "chunk_id": "lexi-atorvastatin-2018#ddi-macrolides",
            "relevance_score": 1.0,
            "is_essential": true,
            "note": null
          }
        ],
        "drug_names": [
          "atorvastatin"
        ],
        "tags": [
          "interaction"
        ],
        "source_note": null,
        "reasoning": null,
        "gold": {
          "interactions": [
            {
              "drug": "clarithromycin",
              "mechanism": "strong CYP3A4 inhibition",
              "severity": "major",
              "action": "avoid coadministration; if unavoidable, hold atorvastatin or use lowest dose with monitoring"
            }
          ],
          "contraindications": [],
          "recency_risk": false,
          "citations": [
            "lexi-atorvastatin-2018#ddi-macrolides"
          ]
        },
        "oracle_context": [
          {
            "chunk_id": "lexi-atorvastatin-2018#ddi-macrolides",
            "role": "support",
            "text": "Clarithromycin is a strong CYP3A4 inhibitor; coadministration increases atorvastatin levels and myopathy/rhabdomyolysis risk. Avoid; if unavoidable, hold or use the lowest dose with close monitoring."
          },
          {
            "chunk_id": "lexi-atorvastatin-2018#ddi-azithro",
            "role": "distractor",
            "text": "Azithromycin has little CYP3A4 inhibition and is not a suitable proxy for clarithromycin interactions."
          }
        ],
        "judge_metadata": {
          "allowed_chunk_ids": [
            "lexi-atorvastatin-2018#ddi-macrolides"
          ],
          "disallowed_chunk_ids": [
            "lexi-atorvastatin-2018#ddi-azithro"
          ]
        }
      },
      "generated_answer": "{\n  \"dose_per_dose_mg\": null,\n  \"volume_per_dose_mL\": null,\n  \"frequency\": null,\n  \"max_daily_mg\": null,\n  \"rounding\": \"Not applicable\",\n  \"calc_rule\": \"Strong CYP3A4 inhibition increases atorvastatin levels and myopathy/rhabdomyolysis risk; avoid; if unavoidable, hold or use the lowest dose with close monitoring\",\n  \"citations\": [\"lexi-atorvastatin-2018#ddi-macrolides\"],\n  \"notes\": \"Avoid coadministration of clarithromycin with atorvastatin due to increased risk of myopathy/rhabdomyolysis; if unavoidable, hold or use the lowest dose with close monitoring\"\n}",
      "expected_answer": "Major interaction (strong CYP3A4 inhibitor). Avoid coadministration; if unavoidable, hold atorvastatin or limit to the lowest dose and monitor for myopathy.",
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "precision_at_k": {
          "1": 1.0,
          "3": 0.5,
          "5": 0.5,
          "10": 0.5,
          "20": 0.5
        },
        "mean_reciprocal_rank": 1.0,
        "average_precision": 1.0,
        "ndcg_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "essential_recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "first_relevant_rank": 1,
        "total_relevant": 1,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.05262474629009886,
        "rouge_1_f1": 0.3368421052631579,
        "rouge_2_f1": 0.12903225806451613,
        "rouge_l_f1": 0.25263157894736843,
        "semantic_similarity": 0.621039867401123,
        "key_points_covered": 0.6666666666666666,
        "key_points_found": [
          "Mechanism: strong CYP3A4 inhibition",
          "Action: avoid; if unavoidable hold or use lowest dose with monitoring"
        ],
        "key_points_missing": [
          "Severity: major"
        ],
        "answer_length": 61,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "retrieval_results": [
        {
          "chunk_id": "lexi-atorvastatin-2018#ddi-macrolides",
          "score": 0.0,
          "rank": 1
        },
        {
          "chunk_id": "lexi-atorvastatin-2018#ddi-azithro",
          "score": 0.0,
          "rank": 2
        }
      ],
      "context_chunks": [
        {
          "chunk_id": "lexi-atorvastatin-2018#ddi-macrolides",
          "role": "support",
          "text": "Clarithromycin is a strong CYP3A4 inhibitor; coadministration increases atorvastatin levels and myopathy/rhabdomyolysis risk. Avoid; if unavoidable, hold or use the lowest dose with close monitoring."
        },
        {
          "chunk_id": "lexi-atorvastatin-2018#ddi-azithro",
          "role": "distractor",
          "text": "Azithromycin has little CYP3A4 inhibition and is not a suitable proxy for clarithromycin interactions."
        }
      ],
      "failure_analysis": {
        "question_id": "q009",
        "question": "Patient on atorvastatin needs clarithromycin. What’s the risk and action?",
        "failure_types": [
          "retrieval_irrelevant",
          "qa_incorrect",
          "qa_incomplete"
        ],
        "retrieved_chunks": [
          {
            "chunk_id": "lexi-atorvastatin-2018#ddi-macrolides",
            "score": 0.0,
            "rank": 1
          },
          {
            "chunk_id": "lexi-atorvastatin-2018#ddi-azithro",
            "score": 0.0,
            "rank": 2
          }
        ],
        "relevant_chunks_found": [
          "lexi-atorvastatin-2018#ddi-macrolides"
        ],
        "essential_chunks_missed": [],
        "generated_answer": "{\n  \"dose_per_dose_mg\": null,\n  \"volume_per_dose_mL\": null,\n  \"frequency\": null,\n  \"max_daily_mg\": null,\n  \"rounding\": \"Not applicable\",\n  \"calc_rule\": \"Strong CYP3A4 inhibition increases atorvastatin levels and myopathy/rhabdomyolysis risk; avoid; if unavoidable, hold or use the lowest dose with close monitoring\",\n  \"citations\": [\"lexi-atorvastatin-2018#ddi-macrolides\"],\n  \"notes\": \"Avoid coadministration of clarithromycin with atorvastatin due to increased risk of myopathy/rhabdomyolysis; if unavoidable, hold or use the lowest dose with close monitoring\"\n}",
        "expected_answer": "Major interaction (strong CYP3A4 inhibitor). Avoid coadministration; if unavoidable, hold atorvastatin or limit to the lowest dose and monitor for myopathy.",
        "key_points_missing": [
          "Severity: major"
        ],
        "retrieval_metrics": {
          "recall_at_k": {
            "1": 1.0,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "precision_at_k": {
            "1": 1.0,
            "3": 0.5,
            "5": 0.5,
            "10": 0.5,
            "20": 0.5
          },
          "mean_reciprocal_rank": 1.0,
          "average_precision": 1.0,
          "ndcg_at_k": {
            "1": 1.0,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "essential_recall_at_k": {
            "1": 1.0,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "first_relevant_rank": 1,
          "total_relevant": 1,
          "total_essential": 1
        },
        "qa_metrics": {
          "bleu_score": 0.05262474629009886,
          "rouge_1_f1": 0.3368421052631579,
          "rouge_2_f1": 0.12903225806451613,
          "rouge_l_f1": 0.25263157894736843,
          "semantic_similarity": 0.621039867401123,
          "key_points_covered": 0.6666666666666666,
          "key_points_found": [
            "Mechanism: strong CYP3A4 inhibition",
            "Action: avoid; if unavoidable hold or use lowest dose with monitoring"
          ],
          "key_points_missing": [
            "Severity: major"
          ],
          "answer_length": 61,
          "has_answer": true,
          "factual_accuracy": null,
          "helpfulness": null
        },
        "root_cause": "both_systems",
        "severity": "high",
        "notes": null
      }
    },
    {
      "question_id": "q010",
      "question": {
        "id": "q010",
        "question": "Starting linezolid in a patient on sertraline. Is this safe?",
        "question_type": "interaction",
        "difficulty": "medium",
        "expected_answer": "Major interaction: risk of serotonin syndrome (linezolid has MAOI activity). Avoid; if benefits outweigh risks, withhold SSRI or monitor very closely.",
        "answer_key_points": [
          "Mechanism: MAOI activity → ↑serotonin",
          "Severity: major",
          "Action: avoid; or stop SSRI/close monitoring if unavoidable"
        ],
        "relevant_chunks": [
          {
            "chunk_id": "lexi-linezolid-2018#ddi-ssri",
            "relevance_score": 1.0,
            "is_essential": true,
            "note": null
          }
        ],
        "drug_names": [
          "linezolid"
        ],
        "tags": [
          "interaction"
        ],
        "source_note": null,
        "reasoning": null,
        "gold": {
          "interactions": [
            {
              "drug": "sertraline (SSRI)",
              "mechanism": "MAOI activity of linezolid → ↑serotonin",
              "severity": "major",
              "action": "avoid combination; if unavoidable, withhold SSRI or monitor closely"
            }
          ],
          "contraindications": [],
          "recency_risk": false,
          "citations": [
            "lexi-linezolid-2018#ddi-ssri"
          ]
        },
        "oracle_context": [
          {
            "chunk_id": "lexi-linezolid-2018#ddi-ssri",
            "role": "support",
            "text": "Linezolid has reversible MAOI activity and may precipitate serotonin syndrome with SSRIs. Avoid combination; if benefits outweigh risks, withhold SSRI and monitor closely."
          },
          {
            "chunk_id": "lexi-linezolid-2018#ddi-penicillins",
            "role": "distractor",
            "text": "No serotonergic interaction with penicillins; this is not relevant to SSRI risk."
          }
        ],
        "judge_metadata": {
          "allowed_chunk_ids": [
            "lexi-linezolid-2018#ddi-ssri"
          ],
          "disallowed_chunk_ids": [
            "lexi-linezolid-2018#ddi-penicillins"
          ]
        }
      },
      "generated_answer": "{\n  \"dose_per_dose_mg\": null,\n  \"volume_per_dose_mL\": null,\n  \"frequency\": null,\n  \"max_daily_mg\": null,\n  \"rounding\": \"Not applicable\",\n  \"calc_rule\": \"Avoid combination due to Linezolid's reversible MAOI activity precipitating serotonin syndrome with SSRIs\",\n  \"citations\": [\"lexi-linezolid-2018#ddi-ssri\"],\n  \"notes\": \"Avoid Linezolid in patients on Sertraline due to risk of serotonin syndrome\"\n}",
      "expected_answer": "Major interaction: risk of serotonin syndrome (linezolid has MAOI activity). Avoid; if benefits outweigh risks, withhold SSRI or monitor very closely.",
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "precision_at_k": {
          "1": 1.0,
          "3": 0.5,
          "5": 0.5,
          "10": 0.5,
          "20": 0.5
        },
        "mean_reciprocal_rank": 1.0,
        "average_precision": 1.0,
        "ndcg_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "essential_recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "first_relevant_rank": 1,
        "total_relevant": 1,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.03539596914884462,
        "rouge_1_f1": 0.24,
        "rouge_2_f1": 0.10958904109589042,
        "rouge_l_f1": 0.13333333333333333,
        "semantic_similarity": 0.5741615891456604,
        "key_points_covered": 0.0,
        "key_points_found": [],
        "key_points_missing": [
          "Mechanism: MAOI activity → ↑serotonin",
          "Severity: major",
          "Action: avoid; or stop SSRI/close monitoring if unavoidable"
        ],
        "answer_length": 42,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "retrieval_results": [
        {
          "chunk_id": "lexi-linezolid-2018#ddi-ssri",
          "score": 0.0,
          "rank": 1
        },
        {
          "chunk_id": "lexi-linezolid-2018#ddi-penicillins",
          "score": 0.0,
          "rank": 2
        }
      ],
      "context_chunks": [
        {
          "chunk_id": "lexi-linezolid-2018#ddi-ssri",
          "role": "support",
          "text": "Linezolid has reversible MAOI activity and may precipitate serotonin syndrome with SSRIs. Avoid combination; if benefits outweigh risks, withhold SSRI and monitor closely."
        },
        {
          "chunk_id": "lexi-linezolid-2018#ddi-penicillins",
          "role": "distractor",
          "text": "No serotonergic interaction with penicillins; this is not relevant to SSRI risk."
        }
      ],
      "failure_analysis": {
        "question_id": "q010",
        "question": "Starting linezolid in a patient on sertraline. Is this safe?",
        "failure_types": [
          "retrieval_irrelevant",
          "qa_incorrect",
          "qa_incomplete",
          "e2e_low_quality"
        ],
        "retrieved_chunks": [
          {
            "chunk_id": "lexi-linezolid-2018#ddi-ssri",
            "score": 0.0,
            "rank": 1
          },
          {
            "chunk_id": "lexi-linezolid-2018#ddi-penicillins",
            "score": 0.0,
            "rank": 2
          }
        ],
        "relevant_chunks_found": [
          "lexi-linezolid-2018#ddi-ssri"
        ],
        "essential_chunks_missed": [],
        "generated_answer": "{\n  \"dose_per_dose_mg\": null,\n  \"volume_per_dose_mL\": null,\n  \"frequency\": null,\n  \"max_daily_mg\": null,\n  \"rounding\": \"Not applicable\",\n  \"calc_rule\": \"Avoid combination due to Linezolid's reversible MAOI activity precipitating serotonin syndrome with SSRIs\",\n  \"citations\": [\"lexi-linezolid-2018#ddi-ssri\"],\n  \"notes\": \"Avoid Linezolid in patients on Sertraline due to risk of serotonin syndrome\"\n}",
        "expected_answer": "Major interaction: risk of serotonin syndrome (linezolid has MAOI activity). Avoid; if benefits outweigh risks, withhold SSRI or monitor very closely.",
        "key_points_missing": [
          "Mechanism: MAOI activity → ↑serotonin",
          "Severity: major",
          "Action: avoid; or stop SSRI/close monitoring if unavoidable"
        ],
        "retrieval_metrics": {
          "recall_at_k": {
            "1": 1.0,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "precision_at_k": {
            "1": 1.0,
            "3": 0.5,
            "5": 0.5,
            "10": 0.5,
            "20": 0.5
          },
          "mean_reciprocal_rank": 1.0,
          "average_precision": 1.0,
          "ndcg_at_k": {
            "1": 1.0,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "essential_recall_at_k": {
            "1": 1.0,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "first_relevant_rank": 1,
          "total_relevant": 1,
          "total_essential": 1
        },
        "qa_metrics": {
          "bleu_score": 0.03539596914884462,
          "rouge_1_f1": 0.24,
          "rouge_2_f1": 0.10958904109589042,
          "rouge_l_f1": 0.13333333333333333,
          "semantic_similarity": 0.5741615891456604,
          "key_points_covered": 0.0,
          "key_points_found": [],
          "key_points_missing": [
            "Mechanism: MAOI activity → ↑serotonin",
            "Severity: major",
            "Action: avoid; or stop SSRI/close monitoring if unavoidable"
          ],
          "answer_length": 42,
          "has_answer": true,
          "factual_accuracy": null,
          "helpfulness": null
        },
        "root_cause": "both_systems",
        "severity": "high",
        "notes": null
      }
    },
    {
      "question_id": "q011",
      "question": {
        "id": "q011",
        "question": "Patient on digoxin will start amiodarone. What’s the interaction management?",
        "question_type": "interaction",
        "difficulty": "medium",
        "expected_answer": "Major interaction (P-gp inhibition). Reduce digoxin dose by ~30–50% and monitor levels/ECG.",
        "answer_key_points": [
          "Mechanism: P-gp inhibition → ↑digoxin",
          "Severity: major",
          "Action: reduce dose ~30–50% + monitor levels and ECG"
        ],
        "relevant_chunks": [
          {
            "chunk_id": "lexi-digoxin-2018#ddi-amio",
            "relevance_score": 1.0,
            "is_essential": true,
            "note": null
          }
        ],
        "drug_names": [
          "digoxin"
        ],
        "tags": [
          "interaction"
        ],
        "source_note": null,
        "reasoning": null,
        "gold": {
          "interactions": [
            {
              "drug": "amiodarone",
              "mechanism": "P-gp inhibition → ↑digoxin levels",
              "severity": "major",
              "action": "reduce digoxin dose by ~30–50% and monitor serum levels and ECG"
            }
          ],
          "contraindications": [],
          "recency_risk": false,
          "citations": [
            "lexi-digoxin-2018#ddi-amio"
          ]
        },
        "oracle_context": [
          {
            "chunk_id": "lexi-digoxin-2018#ddi-amio",
            "role": "support",
            "text": "Amiodarone inhibits P-gp, increasing digoxin exposure. Reduce digoxin dose by ~30–50% and monitor serum levels, renal function, and ECG."
          },
          {
            "chunk_id": "lexi-digoxin-2018#ddi-verapamil",
            "role": "distractor",
            "text": "Verapamil also raises digoxin via P-gp inhibition, but this does not address amiodarone-specific management."
          }
        ],
        "judge_metadata": {
          "allowed_chunk_ids": [
            "lexi-digoxin-2018#ddi-amio"
          ],
          "disallowed_chunk_ids": [
            "lexi-digoxin-2018#ddi-verapamil"
          ]
        }
      },
      "generated_answer": "{\n  \"dose_per_dose_mg\": null,\n  \"volume_per_dose_mL\": null,\n  \"frequency\": \"qd\",\n  \"max_daily_mg\": null,\n  \"rounding\": \"Not applicable\",\n  \"calc_rule\": \"P-gp inhibition ↑ digoxin dose by ~30-50%, monitor serum levels, renal function, and ECG (3 criteria met)\",\n  \"citations\": [\"lexi-digoxin-2018#ddi-amio\"],\n  \"notes\": \"Reduce digoxin dose by 30-50% when starting amiodarone, monitor digoxin levels, renal function, and ECG\"",
      "expected_answer": "Major interaction (P-gp inhibition). Reduce digoxin dose by ~30–50% and monitor levels/ECG.",
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "precision_at_k": {
          "1": 1.0,
          "3": 0.5,
          "5": 0.5,
          "10": 0.5,
          "20": 0.5
        },
        "mean_reciprocal_rank": 1.0,
        "average_precision": 1.0,
        "ndcg_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "essential_recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "first_relevant_rank": 1,
        "total_relevant": 1,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.030177341354967666,
        "rouge_1_f1": 0.33766233766233766,
        "rouge_2_f1": 0.18666666666666668,
        "rouge_l_f1": 0.3116883116883117,
        "semantic_similarity": 0.7093247175216675,
        "key_points_covered": 0.3333333333333333,
        "key_points_found": [
          "Action: reduce dose ~30–50% + monitor levels and ECG"
        ],
        "key_points_missing": [
          "Mechanism: P-gp inhibition → ↑digoxin",
          "Severity: major"
        ],
        "answer_length": 48,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "retrieval_results": [
        {
          "chunk_id": "lexi-digoxin-2018#ddi-amio",
          "score": 0.0,
          "rank": 1
        },
        {
          "chunk_id": "lexi-digoxin-2018#ddi-verapamil",
          "score": 0.0,
          "rank": 2
        }
      ],
      "context_chunks": [
        {
          "chunk_id": "lexi-digoxin-2018#ddi-amio",
          "role": "support",
          "text": "Amiodarone inhibits P-gp, increasing digoxin exposure. Reduce digoxin dose by ~30–50% and monitor serum levels, renal function, and ECG."
        },
        {
          "chunk_id": "lexi-digoxin-2018#ddi-verapamil",
          "role": "distractor",
          "text": "Verapamil also raises digoxin via P-gp inhibition, but this does not address amiodarone-specific management."
        }
      ],
      "failure_analysis": {
        "question_id": "q011",
        "question": "Patient on digoxin will start amiodarone. What’s the interaction management?",
        "failure_types": [
          "retrieval_irrelevant",
          "qa_incomplete"
        ],
        "retrieved_chunks": [
          {
            "chunk_id": "lexi-digoxin-2018#ddi-amio",
            "score": 0.0,
            "rank": 1
          },
          {
            "chunk_id": "lexi-digoxin-2018#ddi-verapamil",
            "score": 0.0,
            "rank": 2
          }
        ],
        "relevant_chunks_found": [
          "lexi-digoxin-2018#ddi-amio"
        ],
        "essential_chunks_missed": [],
        "generated_answer": "{\n  \"dose_per_dose_mg\": null,\n  \"volume_per_dose_mL\": null,\n  \"frequency\": \"qd\",\n  \"max_daily_mg\": null,\n  \"rounding\": \"Not applicable\",\n  \"calc_rule\": \"P-gp inhibition ↑ digoxin dose by ~30-50%, monitor serum levels, renal function, and ECG (3 criteria met)\",\n  \"citations\": [\"lexi-digoxin-2018#ddi-amio\"],\n  \"notes\": \"Reduce digoxin dose by 30-50% when starting amiodarone, monitor digoxin levels, renal function, and ECG\"",
        "expected_answer": "Major interaction (P-gp inhibition). Reduce digoxin dose by ~30–50% and monitor levels/ECG.",
        "key_points_missing": [
          "Mechanism: P-gp inhibition → ↑digoxin",
          "Severity: major"
        ],
        "retrieval_metrics": {
          "recall_at_k": {
            "1": 1.0,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "precision_at_k": {
            "1": 1.0,
            "3": 0.5,
            "5": 0.5,
            "10": 0.5,
            "20": 0.5
          },
          "mean_reciprocal_rank": 1.0,
          "average_precision": 1.0,
          "ndcg_at_k": {
            "1": 1.0,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "essential_recall_at_k": {
            "1": 1.0,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "first_relevant_rank": 1,
          "total_relevant": 1,
          "total_essential": 1
        },
        "qa_metrics": {
          "bleu_score": 0.030177341354967666,
          "rouge_1_f1": 0.33766233766233766,
          "rouge_2_f1": 0.18666666666666668,
          "rouge_l_f1": 0.3116883116883117,
          "semantic_similarity": 0.7093247175216675,
          "key_points_covered": 0.3333333333333333,
          "key_points_found": [
            "Action: reduce dose ~30–50% + monitor levels and ECG"
          ],
          "key_points_missing": [
            "Mechanism: P-gp inhibition → ↑digoxin",
            "Severity: major"
          ],
          "answer_length": 48,
          "has_answer": true,
          "factual_accuracy": null,
          "helpfulness": null
        },
        "root_cause": "both_systems",
        "severity": "medium",
        "notes": null
      }
    },
    {
      "question_id": "q012",
      "question": {
        "id": "q012",
        "question": "COVID-19 patient asks for Paxlovid dosing and interaction checks.",
        "question_type": "dosage",
        "difficulty": "medium",
        "expected_answer": "ABSTAIN. Not in ≤2018 corpus; recency-sensitive therapy. Advise consulting current guidance/pharmacist.",
        "answer_key_points": [
          "Explicit abstention",
          "Sets recency_risk = true",
          "Advises pharmacist/current guidance"
        ],
        "relevant_chunks": [],
        "drug_names": [
          "nirmatrelvir/ritonavir (Paxlovid)"
        ],
        "tags": [
          "dosage"
        ],
        "source_note": null,
        "reasoning": null,
        "gold": {
          "abstain_expected": true,
          "reason": "Not present in ≤2018 corpus; recency-sensitive",
          "recency_risk": true,
          "citations": []
        },
        "oracle_context": [
          {
            "chunk_id": "kb-scope-2018#covid-absent",
            "role": "support",
            "text": "The corpus predates COVID-19 therapies (e.g., nirmatrelvir/ritonavir). This is recency-sensitive; abstain and refer to current guidance/pharmacist."
          }
        ],
        "judge_metadata": {
          "allowed_chunk_ids": [
            "kb-scope-2018#covid-absent"
          ],
          "disallowed_chunk_ids": []
        }
      },
      "generated_answer": "{\n  \"dose_per_dose_mg\": null,\n  \"volume_per_dose_mL\": null,\n  \"frequency\": \"q12h\",\n  \"max_daily_mg\": null,\n  \"rounding\": \"Rounded to whole tablet\",\n  \"calc_rule\": \"Recency-sensitive; abstain and refer to current guidance/pharmacist\",\n  \"citations\": [\"kb-scope-2018#covid-absent\"],\n  \"notes\": \"COVID-19 therapies (e.g., nirmatrelvir/ritonavir) are not covered in this context; refer to current guidance.\"",
      "expected_answer": "ABSTAIN. Not in ≤2018 corpus; recency-sensitive therapy. Advise consulting current guidance/pharmacist.",
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "precision_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "mean_reciprocal_rank": 0.0,
        "average_precision": 0.0,
        "ndcg_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "essential_recall_at_k": {
          "1": 0.0,
          "3": 0.0,
          "5": 0.0,
          "10": 0.0,
          "20": 0.0
        },
        "first_relevant_rank": 0.0,
        "total_relevant": 0,
        "total_essential": 0
      },
      "qa_metrics": {
        "bleu_score": 0.006009853514400763,
        "rouge_1_f1": 0.2898550724637681,
        "rouge_2_f1": 0.08955223880597014,
        "rouge_l_f1": 0.14492753623188406,
        "semantic_similarity": 0.47531673312187195,
        "key_points_covered": 0.0,
        "key_points_found": [],
        "key_points_missing": [
          "Explicit abstention",
          "Sets recency_risk = true",
          "Advises pharmacist/current guidance"
        ],
        "answer_length": 39,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "retrieval_results": [
        {
          "chunk_id": "kb-scope-2018#covid-absent",
          "score": 0.0,
          "rank": 1
        }
      ],
      "context_chunks": [
        {
          "chunk_id": "kb-scope-2018#covid-absent",
          "role": "support",
          "text": "The corpus predates COVID-19 therapies (e.g., nirmatrelvir/ritonavir). This is recency-sensitive; abstain and refer to current guidance/pharmacist."
        }
      ],
      "failure_analysis": {
        "question_id": "q012",
        "question": "COVID-19 patient asks for Paxlovid dosing and interaction checks.",
        "failure_types": [
          "retrieval_miss",
          "retrieval_irrelevant",
          "qa_incorrect",
          "qa_incomplete",
          "e2e_low_quality"
        ],
        "retrieved_chunks": [
          {
            "chunk_id": "kb-scope-2018#covid-absent",
            "score": 0.0,
            "rank": 1
          }
        ],
        "relevant_chunks_found": [],
        "essential_chunks_missed": [],
        "generated_answer": "{\n  \"dose_per_dose_mg\": null,\n  \"volume_per_dose_mL\": null,\n  \"frequency\": \"q12h\",\n  \"max_daily_mg\": null,\n  \"rounding\": \"Rounded to whole tablet\",\n  \"calc_rule\": \"Recency-sensitive; abstain and refer to current guidance/pharmacist\",\n  \"citations\": [\"kb-scope-2018#covid-absent\"],\n  \"notes\": \"COVID-19 therapies (e.g., nirmatrelvir/ritonavir) are not covered in this context; refer to current guidance.\"",
        "expected_answer": "ABSTAIN. Not in ≤2018 corpus; recency-sensitive therapy. Advise consulting current guidance/pharmacist.",
        "key_points_missing": [
          "Explicit abstention",
          "Sets recency_risk = true",
          "Advises pharmacist/current guidance"
        ],
        "retrieval_metrics": {
          "recall_at_k": {
            "1": 0.0,
            "3": 0.0,
            "5": 0.0,
            "10": 0.0,
            "20": 0.0
          },
          "precision_at_k": {
            "1": 0.0,
            "3": 0.0,
            "5": 0.0,
            "10": 0.0,
            "20": 0.0
          },
          "mean_reciprocal_rank": 0.0,
          "average_precision": 0.0,
          "ndcg_at_k": {
            "1": 0.0,
            "3": 0.0,
            "5": 0.0,
            "10": 0.0,
            "20": 0.0
          },
          "essential_recall_at_k": {
            "1": 0.0,
            "3": 0.0,
            "5": 0.0,
            "10": 0.0,
            "20": 0.0
          },
          "first_relevant_rank": 0.0,
          "total_relevant": 0,
          "total_essential": 0
        },
        "qa_metrics": {
          "bleu_score": 0.006009853514400763,
          "rouge_1_f1": 0.2898550724637681,
          "rouge_2_f1": 0.08955223880597014,
          "rouge_l_f1": 0.14492753623188406,
          "semantic_similarity": 0.47531673312187195,
          "key_points_covered": 0.0,
          "key_points_found": [],
          "key_points_missing": [
            "Explicit abstention",
            "Sets recency_risk = true",
            "Advises pharmacist/current guidance"
          ],
          "answer_length": 39,
          "has_answer": true,
          "factual_accuracy": null,
          "helpfulness": null
        },
        "root_cause": "both_systems",
        "severity": "high",
        "notes": null
      }
    },
    {
      "question_id": "q013",
      "question": {
        "id": "q013",
        "question": "What is the current first-line pharmacologic therapy per latest hypertension guidelines?",
        "question_type": "guideline",
        "difficulty": "medium",
        "expected_answer": "ABSTAIN if asked for ‘current’ guidance (2018 corpus includes JNC8/2014). Flag recency risk.",
        "answer_key_points": [
          "Explicit abstention for ‘current’ guideline ask",
          "Recognize JNC8 (2014) is outdated for ‘current’",
          "Sets recency_risk = true"
        ],
        "relevant_chunks": [
          {
            "chunk_id": "lexi-hypertension-2014#jnc8",
            "relevance_score": 1.0,
            "is_essential": true,
            "note": null
          }
        ],
        "drug_names": [],
        "tags": [
          "guideline"
        ],
        "source_note": null,
        "reasoning": null,
        "gold": {
          "abstain_expected": true,
          "reason": "Question seeks guidance newer than 2018; corpus includes JNC8 (2014) only",
          "recency_risk": true,
          "citations": [
            "lexi-hypertension-2014#jnc8"
          ]
        },
        "oracle_context": [
          {
            "chunk_id": "lexi-hypertension-2014#jnc8",
            "role": "support",
            "text": "Corpus contains JNC8 (2014) content. If the question asks for the *current* guideline, abstain and flag recency risk rather than quoting outdated recommendations."
          }
        ],
        "judge_metadata": {
          "allowed_chunk_ids": [
            "lexi-hypertension-2014#jnc8"
          ],
          "disallowed_chunk_ids": []
        }
      },
      "generated_answer": "{\n  \"dose_per_dose_mg\": null,\n  \"volume_per_dose_mL\": null,\n  \"frequency\": \"q12h\",\n  \"max_daily_mg\": null,\n  \"rounding\": \"Rounded to nearest whole number\",\n  \"calc_rule\": \"First-line pharmacologic therapy per JNC8 (2014) guidelines not recommended as current; recency_risk = true\",\n  \"citations\": [\"lexi-hypertension-2014#jnc8\"],\n  \"notes\": \"First-line pharmacologic therapy per JNC8 (2014) is not the current recommendation due to recency risk.\"\n}",
      "expected_answer": "ABSTAIN if asked for ‘current’ guidance (2018 corpus includes JNC8/2014). Flag recency risk.",
      "retrieval_metrics": {
        "recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "precision_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "mean_reciprocal_rank": 1.0,
        "average_precision": 1.0,
        "ndcg_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "essential_recall_at_k": {
          "1": 1.0,
          "3": 1.0,
          "5": 1.0,
          "10": 1.0,
          "20": 1.0
        },
        "first_relevant_rank": 1,
        "total_relevant": 1,
        "total_essential": 1
      },
      "qa_metrics": {
        "bleu_score": 0.010626422039392276,
        "rouge_1_f1": 0.13333333333333333,
        "rouge_2_f1": 0.0547945205479452,
        "rouge_l_f1": 0.13333333333333333,
        "semantic_similarity": 0.4396207928657532,
        "key_points_covered": 0.3333333333333333,
        "key_points_found": [
          "Sets recency_risk = true"
        ],
        "key_points_missing": [
          "Explicit abstention for ‘current’ guideline ask",
          "Recognize JNC8 (2014) is outdated for ‘current’"
        ],
        "answer_length": 49,
        "has_answer": true,
        "factual_accuracy": null,
        "helpfulness": null
      },
      "retrieval_results": [
        {
          "chunk_id": "lexi-hypertension-2014#jnc8",
          "score": 0.0,
          "rank": 1
        }
      ],
      "context_chunks": [
        {
          "chunk_id": "lexi-hypertension-2014#jnc8",
          "role": "support",
          "text": "Corpus contains JNC8 (2014) content. If the question asks for the *current* guideline, abstain and flag recency risk rather than quoting outdated recommendations."
        }
      ],
      "failure_analysis": {
        "question_id": "q013",
        "question": "What is the current first-line pharmacologic therapy per latest hypertension guidelines?",
        "failure_types": [
          "qa_incorrect",
          "qa_incomplete",
          "e2e_low_quality"
        ],
        "retrieved_chunks": [
          {
            "chunk_id": "lexi-hypertension-2014#jnc8",
            "score": 0.0,
            "rank": 1
          }
        ],
        "relevant_chunks_found": [
          "lexi-hypertension-2014#jnc8"
        ],
        "essential_chunks_missed": [],
        "generated_answer": "{\n  \"dose_per_dose_mg\": null,\n  \"volume_per_dose_mL\": null,\n  \"frequency\": \"q12h\",\n  \"max_daily_mg\": null,\n  \"rounding\": \"Rounded to nearest whole number\",\n  \"calc_rule\": \"First-line pharmacologic therapy per JNC8 (2014) guidelines not recommended as current; recency_risk = true\",\n  \"citations\": [\"lexi-hypertension-2014#jnc8\"],\n  \"notes\": \"First-line pharmacologic therapy per JNC8 (2014) is not the current recommendation due to recency risk.\"\n}",
        "expected_answer": "ABSTAIN if asked for ‘current’ guidance (2018 corpus includes JNC8/2014). Flag recency risk.",
        "key_points_missing": [
          "Explicit abstention for ‘current’ guideline ask",
          "Recognize JNC8 (2014) is outdated for ‘current’"
        ],
        "retrieval_metrics": {
          "recall_at_k": {
            "1": 1.0,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "precision_at_k": {
            "1": 1.0,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "mean_reciprocal_rank": 1.0,
          "average_precision": 1.0,
          "ndcg_at_k": {
            "1": 1.0,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "essential_recall_at_k": {
            "1": 1.0,
            "3": 1.0,
            "5": 1.0,
            "10": 1.0,
            "20": 1.0
          },
          "first_relevant_rank": 1,
          "total_relevant": 1,
          "total_essential": 1
        },
        "qa_metrics": {
          "bleu_score": 0.010626422039392276,
          "rouge_1_f1": 0.13333333333333333,
          "rouge_2_f1": 0.0547945205479452,
          "rouge_l_f1": 0.13333333333333333,
          "semantic_similarity": 0.4396207928657532,
          "key_points_covered": 0.3333333333333333,
          "key_points_found": [
            "Sets recency_risk = true"
          ],
          "key_points_missing": [
            "Explicit abstention for ‘current’ guideline ask",
            "Recognize JNC8 (2014) is outdated for ‘current’"
          ],
          "answer_length": 49,
          "has_answer": true,
          "factual_accuracy": null,
          "helpfulness": null
        },
        "root_cause": "qa_system",
        "severity": "high",
        "notes": null
      }
    }
  ]
}